Peptide,~, Vol, 4. Copyright ~ 1983 by A N K H O International Inc. Printed in the U.S.A.

P E P T I D E S

Index to

VOLUME 4

PEPTIDES

VOLUME 4 NUMBER 1 CONTENTS

JANUARY/FEBRUARY 1983

Cholecystokinin and bombesin effects on rewarded and nonrewarded operants. HSIAO, S. and D. D E U P R E E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Absorption of a-MSH from subcutaneous and intraperitoneal sites in the rat. WRIGHT, A. and J. F. W I L S O N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Can ACTH analogs support discriminative learning in rats? S C H E C H T E R , M. D., J. T. CON- C A N N O N , R. E. M A L O N E Y , JR. and L. B E L L U S H . . . . . . . . . . . . . . . . . . . . . . . . . 11

Continuous infusion of cholecystokinin and meal pattern in the rat. HSIAO, S. and C. H. W A N G 15

Shuttlebox avoidance in rhesus monkeys: Effects on plasma cortisol and fl-endorphin. S C A L L E T , A. C., D. R. RUSH, N. H. K A L I N , S. C. RISCH, S. J. SUOMI and T. ZAAS . . . 19

Mechanism of degration of LH-RH and neurotensin by synaptosomal peptidases. McDERMOTT, J. R., A. I. SMITH, P. R. DODD, J. A. HARDY and J. A. E D W A R D S O N . . . . . . . . . . . . 25

Substance P and antinociception. H A L L , M. E. and J. M. STEWART . . . . . . . . . . . . . . . . . . . 31

Vasopressin analog delays extinction of classically conditioned bradycardia. H E R N A N D E Z , L. L. and D. A. P O W E L L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37

Neurotensin interacts with dopaminergic neurons in rat striatum. RECHES, A., R. E. BURKE, D. J IANG, H. R. W A G N E R and S. F A H N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43

Modulation of cholinergic neurotransmitter release from myenteric plexus by somatostatin. YAU, W. M., P. F. L I N G L E and M. L. Y O U T H E R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49

Central and peripheral components of dermorphin's effect on rat intestinal propulsion in comparison to morphine. PAROLARO, D., M. SALA, G. CREMA, L. SPAZZI, R. C E S A N A and E. GORI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55

Activation of angiotensin II receptors in brain potentiates the stimulating effect of endogenous opioid neurons on central sympathetic outflow. APPEL, N. M. and G. R. VAN LOON . . . . . . . 59

Calcitonin--C.N.S. action to control the pattern of intestinal motility in rats. B U E N O , L., J. F I O R A M O N T I and J. P. F E R R E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63

Tolerance to the anti-avoidance properties of cholecystokinin-octapeptide. C O H E N , S. L., M. K N I G H T , C. A. T A M M I N G A and T. N. C H A S E . . . . . . . . . . . . . . . . . . . . . . . . . . 67

Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. II. Solubilization and sep- aration of membrane-bound CCK-8 cleaving enzymes. D E S C H O D T - L A N C K M A N , M., N. D. BUI, D. K O U L I S C H E R , P. P A R O U T A U D and A. D. STROSBERG . . . . . . . . . . . . 71

Relationship between plasma concentrations of immunoreactive beta-endorphin and food intake in rats. DAVIS, J. M., M. T. LOWY, G. K. W. YIM, D. R. LAMB and P. V. M A L V E N 79

Action of anorexigenic peptide injected into the brain: Dissociation of effect on body weight and feeding in the rat. MYERS, R. D., J. R. H E P L E R and W. H O L A H A N . . . . . . . . . . . . . . . . . . . . . 85

VOLUME INDEX

Specific binding to adrenal particulate fraction of cyclo(HistidyI-Proline), a TRH metabolite. BAT- TAINI , F., Y. KOCH, Y. T A K A H A R A and A. P E T E R K O F S K Y . . . . . . . . . . . . . . . 89

Arginine vasotocin induces sexual behavior of newts by acting on cells in the brain. MOORE, F. L. and L. J. M I L L E R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97

Feeding and drinking responses in the golden hamster following treatment with cholecystokinen and angiotensin II. MICELI , M. O. and C. W. M A L S B U R Y . . . . . . . . . . . . . . . . . . . . . . . . . I03

In vitro pituitary hormone releasing activity of 40 residue human pancreatic tumor growth hormone releasing factor. ARIMURA, A., M. D. C U L L E R , C. M. T U R K E L S O N , M. G. L U C I A N O , C. R. THOMAS, N. OBARA, K. GROOT, J. RIVIER and W. V A L E 107

Radioimmunoassay for Lys s, Asn 9, neurotensin 8--13: Tissue and subcellular distribution of immunoreac- tivity in chickens. CARRAWAY, R. E., S. E. R U A N E and R. S. RITSEMA . . . . . . . . 111

ACTHI_.~9 but not naltrexone produces biphasic effects on locomotor activity. BLAIR, R., Z. H. G A L I N A , C. S U T H E R L A N D and Z. AMIT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117

B R I E F C O M M UNICA TIONS

Enkephalin-containing polypeptide levels in normal tensive and SHR rat adrenal glands. DEWALD, D. and R. V. LEWIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121

Endogenous opioid peptide effects on the guinea-pig bUiary tract. OOUCHI , M., H. ASAOKA, T. M I T S U T A K E and M. M I Y A G A W A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125

PEPI'IDES

VOLUME 4 NUMBER 2 MARCH/APRIL 1983 C O N T E N T S

Multiplicity of receptors for vasoactive intestinal polypeptide (VIP): Differential effects of apamin on binding in brain, uterus and liver.

F A H R E N K R U G , J., S. G A M M E L T O F T , P. S T A U N - O L S E N , B. OTTESEN and A. SJOQUIST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133

The use of a steric (Y~) in QSAR calculations for peptide hormones. NADASDI , L. and K. M E D Z I H R A D S Z K Y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137

AIpha-melanocyte stimulating hormone facilitates learning of visual but not auditory discriminations. H A N D E L M A N N , G. E., T. L. O ' D O N O H U E , D. F O R R E S T E R and W. COOK 145

The role of N-acyl groups in the inhibitory activity of LH-RH-analogues. MEZO, I., J. SEPRODI, J. I~RCHEGYI, I. T E P L A N , M. KOVACS and B. F L E R K O . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149

Effect of synthetic porcine gastrin-releasing peptide on plasma levels of immunoreactive cholecystokinin pancreatic polypeptide and gastrin in dogs.

INOUE, K., D. McKAY, H. YAJIMA and P. L. RAYFORD . . . . . . . . . . . . . . . . . . 153

Acute abdominal vagotomy reduces drinking to peripheral but not central angiotensin II. SIMANSKY, K. J. and G. P. SMITH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159

Activation of vasopressinergic and oxytocinergic neurons during aging in the Wistar rat. FLIERS, E. and D. F. SWAAB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165

Mechanism of the cardiovascular response to systemic intravenous administration of leucine-enkephalin in the conscious dog.

GILES, T. D. and G. E. S A N D E R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171

Effects of Thyrotropin-releasing hormone (TRH) and MK-771 on schedule-controlled behavior of squirrel monkeys, rabbits and pigeons.

BARRETT, J. E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177

Circadian effect of ACTH 1-17 on mitotic index of the corneal epithelium of BALB/C mice. S C H E V I N G , L. E., T. H. TSAI, J. E. P A U L Y and F. H A L B E R G . . . . . . . . . . . . 183

des41-13) Human fl-endorphin interacts with calmodulin. PUETT, D., D. P. GIEDROC, S. T O L L E F S O N and N. L I N G . . . . . . . . . . . . . . . . 191

Intracerebroventricular and septal injections of arginine vasopressin are not antipyretic in the rabbit. B E R N A R D I N I , G. L., J. M. L IPTON and W. G. C L A R K . . . . . . . . . . . . . . . . . . . . 195

a-MSH injected into the septal region reduces fever in rabbits. G L Y N - B A L L I N G E R , J. R., G. L. B E R N A R D I N I and J. M. L IPTON . . . . . . . . . 199

Effect of opiate-active substances on pancreatic polypeptide levels in dogs. S C H U S D Z I A R R A , V., R. SCHICK, A. H O L L A N D , A. DE LA F U E N T E , J. SPECHT, V. MAIER, V. B R A N T L and E. F. P F E I F F E R . . . . . . . . . . . . . . . . . . 205

Associated endocrine, physiological and behavioral changes in rhesus monkeys after intravenous corticotropin-releasing factor administration.

K A L I N , N. H., S. E. S H E L T O N , G. W. K R A E M E R and W. T. M c K I N N E Y 211

Contents continued

VOLUME INDEX

Corticotropin-releasing factor administered intraventricularly to rhesus monkeys. K A L I N , N. H . , S. E. S H E L T O N , G. W. K R A E M E R and W. T. M c K I N N E Y 217

Effects of synthetic ovine CRF on ACTH, cortisol and blood pressure in sheep. K A L I N , N. H . , J. C. G O N D E R and S. E. S H E L T O N . . . . . . . . . . . . . . . . . . . . . . . 221

Dynorphins and leu-enkephalin in brain nuclei and pituitary of WKY and SHR rats. F E U E R S T E I N , G . , C. J. M O L I N E A U X , J. G. R O S E N B E R G E R , A. I. F A D E N and B. M. C O X . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225

The coexistence and release of bovine pancreatic polypeptide-like immunoreactivity from noradrenergic superior cervical ganglia neurons.

O L S C H O W K A , J. A. and D. M. J A C O B O W I T Z . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231

Comparison of the effects of TRH and D-Ala2-metenkephalinamide on hippocampal electrical activity and behavior in the unanesthetized rat.

D R U S T , E. G. and I. L. C R A W F O R D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239

Pancreatic polypeptide-like material in nerves and endocrine cells of the rat. T A Y L O R , I. L. and C. R. V A I L L A N T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245

Barbiturate competition for TRH receptors in mouse brain: Neuromodulation of anesthesia. H I R S C H , M. D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255

B R I E F C O M M U N 1 C A T I O N S

Vasopressin potentiates the stimulation of cyclic AMP accumulation by norepinephrine. C H U R C H , A. C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261

Intraventricular administration of antivasopressin serum inhibits retention in mice. L E C C E S E , A. P. and J. L. I S E N H O U R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 265

A N N O U N C E M E N TS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 269

PEFFIDES

VOLUME 4 NUMBER 3 C O N T E N T S

MAY/JUNE 1983

Studies on/]-endorphin and membrane-bound calcium interaction using chlorotetracycline (CTC) as a fluorescence probe.

C H A K R A B A R T I , A. K . , T. K . C H A T T E R J E E and J. J. G H O S H . . . . . . . . . . . . . 273

Central effects of neuropeptides on ventilation in the rat.

N I E W O E H N E R , D. E . , A. S. L E V I N E and J. E. M O R L E Y . . . . . . . . . . . . . . . . . . 277

Effects of deprolorphin, a casomorphin analog, on hippocampal CA1 field potentials in vitro.

R E Y M A N N , K. G . , A. N. C H E P K O V A and H. M A T T H I E S . . . . . . . . . . . . . . . . . 283

Feeding induced by opiates injected into the paraventricular hypothalamus.

M c L E A N , S. and B. G. H O E B E L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 287

Intracerebroventricular somatostatin attenuates electroconvulsive shock-induced amnesia in rats.

VI~CSEI , L . , I. B O L L O K and G. T E L E G D Y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293

Rapid clinical effectiveness of MIF-I in the treatment of major depressive illness.

VAN DER V E L D E , C. D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297

Effect of 41-CRF antiserum on the secretion of ACTH, B-Endorphin and a-MSH in the rat.

C O N T E - D E V O L X , B. , M. R E Y , F. B O U D O U R E S Q U E , P. G I R A U D , E. C A S T A N A S , Y. M I L L E T , J. L . C O D A C C I O N I and C. O L I V E R . . . . . . . . . . . 301

Circadian variation of fl-endorphin-like immunoreactivity in neurointermediate pituitary.

G I B S O N , M. J . , G. J. C O L U R S O , L. A P P L E B A U M and D. T. K R I E G E R . . . . 305

Changes in thyrotropin-releasing hormone levels in alligator stomach during fasting.

B O L A F F I , J. L . , V. L A N C E and I. M. D. J A C K S O N . . . . . . . . . . . . . . . . . . . . . . . 311

Centrally administered N-terminal fragments of ACTH (1-10, 4-10, 4-9) display convulsant properties in rabbits.

T A R T A R A , A . , P. BO, M. M A U R E L L I and F. S A V O L D I . . . . . . . . . . . . . . . . . . . . 315

Isolation from porcine antrai mucosa of a hexapeptide corresponding to the C-terminal sequence of gastrin.

G R E G O R Y , R. A. , G. J. D O C K R A Y , J. R. R E E V E , JR . , J. E. S H I V E L Y and C. M I L L E R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 319

Hyperthermic action of somatostatin-28.

W A K A B A Y A S H I , I . , Y. T O N E G A W A and T. S H I B A S A K I . . . . . . . . . . . . . . . . . . . 325

Extra-hippocampal projections of CCK neurons of the hippocampus and subiculum.

H A N D E L M A N N , G. E . , M. C. B E I N F E L D , T. L . O ' D O N O H U E , J. B. N E L S O N and D. E. B R E N N E M A N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331

Characterization of aH-AVP binding sites in particulate preparations of rat brain.

P E A R L M U T T E R , A. F . , M. G. C O S T A N T I N I and B. L O E S E R . . . . . . . . . . . . . . 335

Contents continued

VOLUME INDEX

The application of an improved solid phase synthetic technique to the delineation of an

antigenic site of apolipoprotein A-II. B H A T N A G A R , P. K . , S. J. T. M A O , A. M. G O T T O , JR. a n d J . T. S P A R R O W 343

Pharmacological manipulation of sincalide (CCK-8)-induced suppression of feeding.

W I L S O N , M. C. , D. D E N S O N , J. A. B E D F O R D and R. N. H U N S I N G E R . . . . 351

Effect of chronic vasopressin treatment on alcohol drinking of Brattleboro HZ and DI rats.

M Y E R S , R. D. , E. C. C R I T C H E R and N. N. C O R N W E L L . . . . . . . . . . . . . . . . . . 359

Isolation and amino acid sequence of two urotensin II peptides from Catostomus Commersoni urophyses.

M c M A S T E R , D. and K. L E D E R I S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 367

Cholinergic role on release and action of motilin.

L E E , K. Y. , H. J. P A R K , T . -M. C H A N G and W. Y. C H E Y . . . . . . . . . . . . . . . . . 375

The effects of pancreatic polypeptides and neuropeptide Y on the rat vas deferens.

O H H A S H I , T. and D. M. J A C O B O W I T Z . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 381

Neuropeptides in the female genital tract: Effect on vascular and non-vascular smooth muscle.

O T T E S E N , B. , B. R. G R A M and J. F A H R E N K R U G . . . . . . . . . . . . . . . . . . . . . . . . . 387

B R I E F C O M M U N I C A T I O N

des-Tyrl-y-Endorphin and haloperidol increase pineal gland melatonin levels in rats.

G A F F O R I , O. , M. G E F F A R D and J. M. VAN R E E . . . . . . . . . . . . . . . . . . . . . . . . . . . 393

A N N O U N C E M E N T S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 397

PEPTIDES

VOLUME 4 NUMBER 4 C O N T E N T S

JULY/AUGUST 1983

L-prolyI-L-arginyl-glycineamide induces memory enhancement in chicks.

DAVIS, J. L., R. M. PICO and A. C H E R K I N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401

Divergent effects of cholecystokinin, bombesin, and lithium on rat exploratory behaviors.

C R A W L E Y , J. N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 405

Oxytocin as well as vasopressin potentiate ovine CRF in vitro.

ANTONI , F. A., M. C. H O L M E S and M. T. JONES . . . . . . . . . . . . . . . . . . . . . . . . 411

Influence of dipeptides on precipitated morphine withdrawal in the mouse.

KOVACS, G. L., L. S Z O N T A G H , L. B A L A S P I R I and G. T E L E G D Y . . . . . . . . . 417

Hyperreflexive behavior in Brattleboro rats.

W A R R E N , P. H. and D. M. G A S H . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 421

Synthesis and biological activity of [D-Trp 6] chicken luteinizing hormone-releasing hormone.

MILLAR, R. P. and J. A. K I N G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425

An investigation of N-terminal pro-opiocortin peptides in the rat pituitary.

JACKSON, S., P. S A L A C I N S K I , J. HOPE and P. J. LOWRY . . . . . . . . . . . . . . . . 431

Does motilin control interdigestive pepsin secretion in the dog?

N A K A Y A , M., T. SUZUKI , H. ARAI, K. W A K A B A Y A S H I and Z. ITOH . . . . 439

Peptide E and other proenkephalin-derived peptides are potent kappa opiate receptor agonists.

QUIRION, R. and A. S. WEISS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 445

The substance P content of peripheral tissues in several mammals.

BUCSICS, A., P. H O L Z E R and F. L E M B E C K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451

Is caerulein amphibian CCK?

D I M A L I N E , R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457

Thymosin al-like peptides: Localization and biochemical characterization in the rat brain and pituitary gland.

P A L A S Z Y N S K I , E. W., T. W. MOODY, T. L. O ' D O N O H U E and A. L. G O L D S T E I N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 463

Different patterns of central and peripheral flEP, flLPH and ACTH throughout life.

F A C C H I N E T T I , F., F. P E T R A G L I A , G. NAPPI , E. M A R T I G N O N I , G. ANTONI , D. PARRINI and A. R. G E N A Z Z A N I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 469

"Joining peptide" of pro-opiomelanocortin. I. Radioimmunoassay and extraction of related peptides from pituitary glands.

ERISMAN, M. D., L. H. L A Z A R U S , G. D. J A H N K E , C. M. SOLDATO and R. P. D I A U G U S T I N E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 475

"Joining peptide" of pro-opiomelanocortin. II. Interspecies heterogeneity of the joining peptide fragment.

J A H N K E , G. D., C. M. SOLDATO, M. D. E R I S M A N , R. P. D I A U G U S T I N E and L. H. L A Z A R U S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 483

Contents continued

VOLUME INDEX

Neurotensin: Effects of hypothalamic and intravenous injections on eating and drinking in rats.

S T A N L E Y , B. G., B. G. H O E B E L and S. F. L E I B O W I T Z . . . . . . . . . . . . . . . . . . . 493

Plasma cortisol and beta-endorphin in horses subjected to electro-acupuncture for cutaneous analgesia.

BOSSUT, D. F. B . , L . S. L E S H I N , M. W. S T R O M B E R G a n d P . V. M A L V E N 501

Presence of vasopressin, oxytocin and neurophysin in the retina of mammals, effect of light and darkness, comparison with the neuropeptide content of the neurohypophysis and the pineal gland.

G A U Q U E L I N , G., G. G E E L E N , F. LOUIS , A. M. A L L E V A R D , C. M E U N I E R , G. C U I S I N A U D , S. B E N J A N E T , N. G. S E I D A H , M. C H R E T I E N , J. J. L E G R O S and C. G H A R I B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509

Antinociceptive action of intrathecal neurotensin in mice.

H Y L D E N , J. L. K. and G. L. W I L C O X . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 517

Localization of GRF-like immunoreactive neurons in the rat brain.

J A C O B O W I T Z , D. M., H. S C H U L T E , G. P. C H R O U S O S and D. L. L O R I A U X 521

Organization and interrelationship of neuropeptides in the central amygdaioid nucleus of the rat.

WRAY, S. and G. E. H O F F M A N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 525

Evidence that (Glu4)-neurotensin is the naturally occurring neurotensin in plasma.

T H E O D O R S S O N - N O R H E I M , E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 543

Cytochemical characterization of pituitary target cells for biotinylated gonadotropin releasing hormone.

C H I L D S (MORIARTY) , G. V., Z. NAOR, E. H A Z U M , R. TIBOLT, K. N. W E S T L U N D and M. B. H A N C O C K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 549

Somatostatin fibers and their relationship to specific cell types (GH and TSH) in the rat anterior pituitary.

W E S T L U N D , K. N., S. C H M I E L O W I E C and G. V. C H I L D S . . . . . . . . . . . . . . . . 557

Endogenous opiates: 1982.

O L S O N , G. A. , R. D. O L S O N and A. J. K A S T I N . . . . . . . . . . . . . . . . . . . . . . . . . . . 563

Antinociceptive, prolactin releasing and intestinal motility inhibiting activities of dermorphin and analogues after subcutaneous administration in the rat.

ROSSI , A. , E. Dl S A L L E , G. BRIATICO, G. A RCA RI , R. DE C A S T I G L I O N E and G. P E R S E O . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 577

B R I E F C O M M U N I C A T I O N S

Indomethacin alters the effects of substance-P and VIP on isolated airway smooth muscle.

R E G A L , J. F. and D. E. J O H N S O N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 581

Failure of gel filtration and HPLC purification to increase levels of immunoreactive TR H in rat brain extracts.

COURT, J. A. , A. I. SMITH, J. R. M c D E R M O T T , J. A. B I G G I N S and J. A. E D W A R D S O N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 585

A N N O U N C E M E N T S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 589

PEPTIDES

VOLUME 4 NUMBER 5 C O N T E N T S

SEPTEMBER/OCTOBER 1983

I n t r o d u c t i o n 593

Opioid regulation of CNS dopaminergic pathways: A review of methodology, receptor types, regional variations and species differences.

WOOD, P. L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595

The actions of opiates in the rat substantia nigra: An electrophysiological analysis.

H O M M E R , D. W. and A. PERT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603

Interactions between neurotensin and dopamine in the brain: An overview.

Q U I R I O N , R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609

T R H : Cardiovascular and sympathetic modulation in brain nuclei of the rat.

F E U E R S T E I N , G., A. H. H A S S E N and A. I. F A D E N . . . . . . . . . . . . . . . . . . . . . . . 617

Differential cardiovascular effects mediated by mu and kappa opiate receptors in hindbrain nuclei.

H A S S E N , A. H., G. F E U E R S T E I N and A. I. F A D E N . . . . . . . . . . . . . . . . . . . . . . . 621

Central cardiovascular effects of mammalian neurohypophyseal peptides in conscious rats.

ZERBE, R. L. , S. K I R T L A N D , A. I. F A D E N and G. F E U E R S T E I N . . . . . . . . . 627

Neuropeptides in spinal cord injury: Comparative experimental models.

F A D E N , A. I., T. P. JACOBS, G. P. SMITH, B. G R E E N and J. A. ZIVIN • . . 6 3 1

Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth.

L E W I S , J. W., Y. SHAVIT , G. W. T E R M A N , L. R. N E L S O N , R. P. G A L E and J. C. L I E B E S K I N D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 635

Enkephalin-containing polypeptides are potent inhibitors of enkephalin degradation.

HUI , K. -S . , M. HUI , M. B A N A Y - S C H W A R T Z , T. D E G U Z M A N , N. L I N G and A. L A J T H A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 639

Predominant involvement of mu- rather than delta- or kappa-opiate receptors in LH secretion.

P F E I F F E R , D. G., A. P F E I F F E R , Y. S H I M O H I G A S H I , G. R. M E R R I A M and D. L. L O R I A U X . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 647

Regulation of opioid gene expression.

C I V E L L I , O., N. B I R N B E R G , M. COMB, J. D O U G L A S S , J. C. L I S S I T Z K Y , M. U H L E R and E. H E R B E R T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 651

Somatostatinergic projections from the central nucleus of the amygdala to the vagal nuclei.

H I G G I N S , G. A. and J. S. S C H W A B E R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657

The morphology of somatostatin-immunoreactive neurons in the lateral nucleus of the rat amygdala.

GRAY, T. S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 663

The effects of cysteamine and capsaicin on somatostatin and substance P in medullary nuclei.

H E L K E , C. J. and J. H. S E L S K Y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 669

Contents continued

VOLUME INDEX

Distribution and origin of bombesin, substance P and somatostatin in cat spinal cord.

M A S S A R I , V. J . , Y. T I Z A B I , C. H. P A R K , T. W. M O O D Y , C. J. H E L K E and T. L. O ' D O N O H U E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 673

Bombesin-like peptides and receptors in human tumor cell lines.

M O O D Y , T. W. , V. B E R T N E S S and D. N. C A R N E Y . . . . . . . . . . . . . . . . . . . . . . . . 683

Bombesin stimulates insulin secretion and reduces food intake in the baboon.

W O O D S , S. C. , L. J. S T E I N , D. P. F 1 G L E W I C Z and D. P O R T E , JR. . . . . . . . . 687

Bombesin-induced behavioural changes: Antagonism by neuroleptics.

M E R A L I , Z. , S. J O H N S T O N and S. Z A L C M A N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 693

Characterization and localization of 3H-arginineS-vasopressin binding to rat kidney and brain tissue.

D O R S A , D. M. , L. A. M A J U M D A R , F. M. P E T R A C C A , D. G. B A S K I N and L. E. C O R N E T T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 699

Vasopressin analog influences the performance of males on a reaction time task.

B E C K W I T H , B. E. , D. I. C O U K and T. S. T I L L . . . . . . . . . . . . . . . . . . . . . . . . . . . . 707

Behavioral differences between vasopressin-deficient (Brattleboro) and normal Long-Evans Rats.

W I L L I A M S , A. R. , R. J. C A R E Y and M. M I L L E R . . . . . . . . . . . . . . . . . . . . . . . . . . 711

Effect of vasopressin on open field and activity behavior of the vasopressin-deficient (Brattleboro) rat.

W I L L I A M S , A. R. , R. J. C A R E Y and M. M I L L E R . . . . . . . . . . . . . . . . . . . . . . . . . . 717

Behavioral effects of [4-Norleucine, 7-D-Phenylalanine]-~-melanocyte-stimulating hormone.

K O B O B U N , K . , T. L. O ' D O N O H U E , G. E. H A N D E L M A N N , T. K. S A W Y E R , V. J. H R U B Y and M. E. H A D L E Y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 721

Influence of MSH and corticosterone on stimulus control over an operant response.

B E C K W I T H , B. E. , A. R U S H I N G and E. A. D E K R E Y . . . . . . . . . . . . . . . . . . . . . . 725

Intracraniai administration of corticotropin-like peptides increases incidence of amphibian reproductive behavior.

M I L L E R , L. J. and F. L. M O O R E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 729

Effects of TRH injection on hippocampal-hypothalamic-pituitary-thyroid interactions.

M U R P H Y , H. M. , C. H. W I D E M A N , D. W. L O N G and T. S. B R O W N . . . . . . 735

Secretin modulation of behavioral and physiological functions in the rat.

C H A R L T O N , C. G. , R. L. M I L L E R , J. N. C R A W L E Y , G. E. H A N D E L M A N N and T. L. O ' D O N O H U E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 739

Nucleus tractus solitarius lesions block the behavioral actions of cholecystokinin.

C R A W L E Y , J. N. and J. S. S C H W A B E R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 743

CCK-8 modulation of mesolimbic dopamine: Antagonism of amphetamine-stimulated behaviors.

S C H N E I D E R , L. H . , J. E. A L P E R T and S. D. I V E R S E N . . . . . . . . . . . . . . . . . . . . 749

Characterization and visualization of cholecystokinin receptors in rat brain using [3H]pentagastrin.

G A U D R E A U , P., R. Q U I R 1 O N , S. S T - P I E R R E and C. B. P E R T . . . . . . . . . . . . . . 755

Substance P and behavior: Opposite effects of N-terminal and C-terminal fragments.

H A L L , M. E. and J. M. S T E W A R T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 763

VOLUME INDEX

The role of substance P-containing fibers in sympathetic ganglia: Effect of capsaicin.

W I L K I N , L. D., L. O. FAGRE, J. Y. JEW and T. H. W I L L I A M S . . . . . . . . . . . 769

Hypothalamic-pituitary-adrenal regulation, neurotransmitters and affective disorders.

J A N O W S K Y , D. S., S. C. RISCH, L. Y. H U E Y , L. L. J U D D a n d J . L. R A U S C H 775

Regulation of ACTH and cortisol in depression.

REUS, V. I., M. JOSEPH and M. D A L L M A N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 785

Muscarinic supersensitivity of anterior pituitary ACTH and B-endorphin release in major depressive illness.

RISCH, S. C., D. S. J A N O W S K Y and J. C. G I L L I N . . . . . . . . . . . . . . . . . . . . . . . . 789

A N N O U N C E M E N TS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 793

PEPTIDES

VOLUME 4 NUMBER 6 C O N T E N T S

NOVEMBER/DECEMBER 1983

Involvement of dynorphin and the kappa opioid receptor in feeding.

MOR LEY, J. E. and A. S. L E V I N E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 797

Thermoregulatory, behavioral and seizure modulatory effects of AVP in the gerbil.

LEE, R. J. and P. L O M A X . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 801

Adrenal modulation of the inhibitory effect of corticotropin releasing factor on feeding.

G O S N E L L , B. A., J. E. M O R L E Y and A. S. L E V I N E . . . . . . . . . . . . . . . . . . . . . . 807

MSH peptides are present in mammalian skin.

THODY, A. J., K. R IDLEY, R. J. P E N N Y , R. C H A L M E R S , C, F I S H E R and S. S H U S T E R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 813

Prolactin-releasing activity of porcine intestinal peptide (PHI-27).

S A M S O N , W. K., M. D. L U M P K I N , J. K. M c D O N A L D and S. M. M c C A N N 817

Proteolytic degradation of gonadotropin-releasing hormone (GnRH) by rat ovarian fractions in vitro.

BERGER, H., K. N I K O L I C S , B. S Z O K E and B. M E H L I S . . . . . . . . . . . . . . . . . . . 821

Vasopressin administration to neonatal rats reduces antidiuretic response in adult kidneys.

H A N D E L M A N N , G. E., J. T. R U S S E L L , H. G A I N E R , R. Z E R B E and M. B A Y O R H . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 827

Peptide-induced excessive grooming in the rat: The role of opiate receptors.

A L O Y O , V. J., B. SPRUIJT, H. Z W I E R S and W. H. G I S P E N . . . . . . . . . . . . . . . . 833

Iontophoretic mapping of corticotropin-releasing factor (CRF) sensitive neurons in the rat forebrain.

EBERLY, L. B., C. A. D U D L E Y and R. L. MOSS . . . . . . . . . . . . . . . . . . . . . . . . . . 837

Renal function and pituitary hormone release during cerebral osmostimulation and TRH in dogs.

H U F F M A N , L. J., G. T. C A M P B E L L and J. P. G I L M O R E . . . . . . . . . . . . . . . . . . 843

Involvement of hypothalamic somatostatin in glucagon-induced suppression of growth hormone secretion in conscious rats.

K A T A K A M I , H., Y. K A T O , N. M A T S U S H I T A , A. S H I M A T S U and H. I M U R A 849

Regional interactions of opioid peptides a t / t and 6 sites in rat brain.

H E W L E T T , W. A. and J. D. B A R C H A S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 853

Actions of intracerebroventricular administration of kyotorphin and an analog on thermoregulation in the mouse.

S A K U R A D A , T., S. S A K U R A D A , S. W A T A N A B E , H. M A T S U M U R A , K. K I S A R A , Y. A K U T S U , Y. S A S A K I and K. S U Z U K I . . . . . . . . . . . . . . . . . . . . . 859

Changes in circadian rhythms of thermoregulation and motor activity in rats as a function of aging: Effects of d-amphetamine and a-MSH.

Y E H U D A , S. and R. L. C A R A S S O . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 865

Immunoreactive peptides related to dynorphin B (=rimorphin) in the rat brain.

ZHU, Y. X., V. H O L L T and H. L O H . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 871

Contents continued

VOLUME INDEX

Biorhythm of arginine-vasopressin in the paraventricular, supraoptic and suprachiasmatic nuclei of rats.

NOTO, T., H. HASHIMOTO, Y. DOI, T. N A K A J I M A and N. KATO . . . . . . . . . 875

Evidence for the presence of immunoreactive histidyl-proline diketopiperazine [Cyclo (His-Pro)] in the adult human brain.

PARKER, C. R., JR., M. MORI, J. PEGUES, C. PRASAD and J. F. W I L B E R 879

A radioimmunoassay specific for [GlnS]LH-RH: Application in the confirmation of the structure of chicken hypothalamic luteinizing hormone-releasing hormone.

KING, J. A., C. J. TOBLER, R. W. ROESKE, W. A. DAY, J. E. RIVIER and R. P. M I L L A R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 883

Biosynthesis of multiple forms of fl-endorphin in the reptile intermediate pituitary.

DORES, R. M. and A. S U R P R E N A N T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 889

Further characterization of the major forms of reptile beta-endorphin.

DORES, R. M . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 897

Studies on bombesin-induced grooming in rats.

GMEREK, D. E. and A. COWAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 907

High concentrations of p-Glu-His-Pro-NHz (thyrotropin-releasing hormone) occur in rat prostate.

PEKARY, A. E., B. SHARP, J. BRIGGS, H. E. CARLSON and J. M. H E R S H M A N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 915

Bovine intermediate pituitary c~-amidation enzyme: Preliminary characterization.

EIPPER, B. A., C. C. G L E M B O T S K I and R. E. MAINS . . . . . . . . . . . . . . . . . . . . . 921

Synthetic hpGRF 1--40 stimulates growth hormone and inhibits prolactin secretion in normal children and children with isolated growth hormone deficiency.

PINTOR, C., V. FANNI , S. LOCHE, V. L O C A T E L L I , S. G. C E L L A , F. VILLA, F. MINUTO, R. CORDA and E. E. M U L L E R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 929

Effect of food-deprivation on rat pancreatic islet cells.

APONTE, G., D. GROSS, G. ROSENQUIST, V. M E N D E L and T. YAMADA 935

Immunohistological detection of degenerating CRF-immunoreactive nerve fibers in the median eminence after lesion of paraventricular nucleus of the rat. A light and electron microscopic study.

LIPOSITS, Zs., I. L E N G V A R I , S. VIGH, A. V. S C H A L L Y and B. F L E R K 0 941

In vivo release of dopamine during perfusion of neurotensin in substantia nigra of the unrestrained rat. MYERS, R. D. and T. F. LEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 955

Biosynthesis of LHRH: Inferences from immunocytochemical studies.

KING, J. C. and E. L. P. A N T H O N Y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 963

B R I E F C O M M U N I C A T I O N

Methionine-enkephalin facilitates the cardiovascular response to epinephrine in the conscious dog. SANDER, G. E., T. D. GILES and J. C. RICE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 971

I N D E X TO V O L U M E 4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 975

Peptides. Vol. 4. Copyright ~' 1983 by ANKHO International Inc. Printed in the U.S.A.

P E P T I D E S VOLUME 4 1983

SUBJECT INDEX

Absorption time, 5 ¢,-MSH metabolism route of administration

Acetylcholine release. 49 caerulein guanidine guinea pig myenteric plexus somatostatin

ACTH age differences, 469 blood pressure, 221 cortisol, 221. 785 41-CRF antiserum, 301 depression, 785. 789 /3-endorphin, 301,469. 789 epilepsy, 315 human studies, 469, 789 hypothalamic-pituitary-adrenal

regulation. 785 ,8-1ipotropin, 469 c~-MSH, 301 muscarinic receptors. 789 ovine CRF. 221 rabbits. 315 sheep, 221

ACTH 1-17. 183 circadian rhythm cornea mitotic index placebo

ACTH~ :~,, 117 biphasic effects locomotor activity naltrexone

ACTH analogues, 11 drug discrimination MSH/ACTH, . , ORG 2766

Adenylate cyclase. 89 adrenal cortex cyclo (His-Pro) specific binding histidyl-proline diketopiperazine monoamine oxidase thyrotropin releasing hormone

Adrenal cortex, 89 adenylate cyclase cyclo (His-Pro) specific binding histidyl-proline diketopiperazine monoamine oxidase thyrotropin releasing hormone

Adrenal glands, 121 enkephalin-containing polypeptide hypertension, spontaneous

Adrenal medulla, 807 corticotropin releasing factor (CRF)

eating vagus nerve

Adrenalectomy bombesin. 907 brain mRNA. 651 glucocorticoid. 651 grooming, 907 hypophysectomy, 907 opioid peptides, 651 solution hybridization, 651

Affective disorders. 775 hypothalamic-pituitary-adrenal axis neurotransmitters

Age differences ACTH. 469 /3-endorphin, 469 human studies, 469 hypothalamo neurohypophyseal

system, 165 ,8-1ipotropin, 469 neurosecretory activity, 165 oxytocin. 165 thiamine pyrophosphatase. 165 vasopressin. 165

Aggression, 763 antinociception C-terminal fragments N-terminal fragments substance

Aging, 865 d-amphetamine circadian rhythms motor activity ~t-MSH therrnoregulation

Alcohol, 563 cardiovascular responses dependence depression drinking eating endogenous opiates epilepsy learning memory schizophrenia shock social behavior stress tolerance

Alligators, 31 I anorexia TRH

Amino acid analysis, 853 bioassay rat prostate

receptor assay t hyrot ropin-releasing hormone

Aminoenkephalinase, 639 peptidase

Amnesia+ 293 electroconvulsive shock passive avoidance somatostatin

cAMP, 261 neuromodulation norepinephrine vasopressin

Amphetamine. 749 cholecystokinin locomotor activity open field

d-Amphetamine, 865 aging circadian rhythms motor activity ~-MSH thermoregulation

Amphibians arginine vasotocin, 97 caerulein, 457 CCK, 457 5 ~-dihydrotestosterone, 97 17/3-estradiol, 97 sexual behavior, male newts, 97 vasopressin antagonists. 97

Amygdala, 657 double labeling somatostatin

Analeptics, 255 anesthesia barbiturates radioligand binding assay thyrotropin releasing hormone

Analgesia dermorphin. 577 electro-acupuncture. 501 horses, 501 intestinal motility. 577

Anesthesia. 255 analeptics barbiturates radioligand binding assay thyrotropin releasing hormone

Angiotensin 11 central sympathetic outflow. 59 cholecystokinin octapeptide. 103 drinking. 103. 159 eating, 103 endogenous opioid neurons. 59 /3-endorphin. 59 hamsters. 103

oxytocin, 137 plasma catecholamines, 59 route of administration, 159 saralasin, 59 steric parameter, 137 structure activity relationship, 137 vagotomy, abdominal, 159

Animal models, 631 endogenous opioids spinal cord injury

Anorexia, 311 alligators TRH

Anorexia nervosa, 85 anorexigenic peptide body weight drinking eating growth hyperthermia metabolism thermoregulation

Anorexigenic peptide, 85 anorexia nervosa body weight drinking eating growth hyperthermia metabolism thermoregulation

Antibodies, 343 antigenic sites apolipoprotein A-II synthetic peptides

Antigenic sites, 343 antibodies apolipoprotein A-I1 synthetic peptides

Antinociception aggression, 763 C-terminal fragments, 763 dose response, 31 naloxone, 31 N-terminal fragments, 763 substance P, 31, 763

Antipyresis, 199 fever ~-MSH rabbits septal region thermoregulation

Antivasopressin serum, 265 memory passive avoidance relention vasopressin

Antral mucosa, 319 gastrin hexapeptide gastrin tetrapeptide isolation

Apamin, 133 cerebral cortex liver, hog neuropeptides uterine smooth muscle, hog vasoactive intestinal polypeptide

binding sites Apolipoprotein A-II, 343

antibodies antigenic sites synthetic peptides

Apparatus. 165 Golgi apparatus

Arginine vasopressin biorhythm, 875 circadian rhythm, 875 gerbil, 801 paraventricular nucleus, 875 seizures, 801 suprachiasmatic nucleus, 875 supraoptic nucleus, 875 thermoregulation, 801

Arginine vasotocin, 97 amphibians 5 ~-dihydrotestosterone 17/?-estradiol sexual behavior, male newts vasopressin antagonists

Autonomic nervous system, 617 cardiovascular responses catecholamines thyrotropin-releasing hormone (TRH)

Autonomic responses. 37 bradycardia, conditioned conditioning, Pavlovian heart rate learning nictitating membrane rabbits vasopressin analogs

Avoidance cholecystokinin octapeptide tolerance

aH-AVP, 335 brain receptors neuropeptide

Baboons, 687 bombesin eating plasma glucose plasma insulin satiety

Bar press, 145 learning memory {~-MSH visual processes Y maze

Barbiturates, 255 analeptics anesthesia radioligand binding assay thyrotropin releasing hormone

Binding assay, 755 cholecystokinin (CCK) laH1Pentagastrin

Bioassay, 853 amino acid analysis rat prostate receptor assay thyrotropin-releasing hormone

Biochemical characterization, 463 peptide localization

Biosynthesis, 963 immunocytochemistry LHRH

Biorhythm. 875 arginine-vasopressin circadian rhythm paraventricular nucleus suprachiasmatic nucleus supraoptic nucleus

Biotinylated GnRH, 549 cytochemical characterization

Biphasic effects, 117 ACTH, :~,

locomotor activity naltrexone

Blood pressure ACTH, 221 cortisol, 221 CRF, 211, 217 endocrine system, 211, 217 heart rate, 627 neurohypophyseal peptides, 627 ovine CRF, 221 rhesus monkeys, 211,217 sheep, 221

Body temperature. 325 bombesin brain monoamines y-MSH somatostatin-28 TRH

Body weight, 85 anorexia nervosa anorexigenic peptide drinking eating growth hyperthermia metabolism thermoregulation

Bombesin adrenalectomy, 907 baboons, 687 bodytemperature, 325 brain monoamines, 325 cancer. 683 cats. 673 cholecystokinin, 405 cholecystokinin octapeptide, I eating, 1,405,687 exploratory behavior, 405 grooming, 907 human studies, 683 hypophysectomy, 907 lithium, 405 locomotor activity, 693 T-MSH. 325 neuroendocrine peptides, 683 neuroleptics, 693 operant behavior, 1 oropharyngeal stimulus, I plasma glucose, 687 plasma insulin. 687 satiety, 1,687 somatostatin, 673 somatostatin-28, 325 spinal cord. 673 substance P, 673 TRH. 325

Bovine intermediate pituitary, 921 molecular oxygen peptide t~-amidation

Bovine joining peptide guinea pigs, 483 joining peptides. 475,483 pituitary, 475 porcine, 483 pro-opiomelanocortin. 475

Bovine pancreatic polypeptide. 231 catecholamine dopamine-,g-hydroxylase superior cervical ganglia

Bradycardia, conditioned, 37 autonomic responses conditioning, Pavlovian heart rate learning nictitating membrane

rabbits vasopressin analogs

Brain accumbens nucleus, 755 adrenal cortex, 89 adrenal medulla, 59, 807,971 amygdala, 525, 657, 663,755 amygdala central nucleus, 225 anterior lobe, 431,557 anterior olfactory nuclei, 755 arcuate nucleus, 521 brain stem, 71,255,699 central nervous system, 739, 879 cerebellum, 71, 335, 585 cerebral cortex, 133,255, 483 cerebral ventricles, 97 claustrum, 755 corpus striatum, 43 cortex, 755, 837 dentate gyrus, 755 dorsomedial nucleus of thalamus. 305,

521 forebrain, 837 fornix, 331 frontal cortex, 71,915 hippocampus, 239, 261,283,331, 335,

735, 879. 915 hypothalamus, 71, 165, 287, 305, 331,

463,483,493,521,585. 617,755, 785, 817, 837, 849, 879, 883,915

lateral nucleus, 663 lateral septum, 837 lateral ventricle, 239 limbic forebrain, 255 medial forebrain bundle, 521 median eminence, 521 medulla oblongata, 335,669 midbrain, 335,915 neurointermediate lobe, 431 nigro-striatal system, 955 nucleus accumbens, 43,609, 749 nucleus ambiguus, 621 nucleus preopticus medialis, 617 nucleus tractus solitarius, 617. 621,

657, 699. 743 olfactory bulb, 71,755 olfactory tubercle, 755 paraventricular nucleus, 165. 225,287,

941 periaqueductal gray, 907 pituitary+ 107, 225,305,431,475, 483 pituitary-adrenal axis, 211, 217. 221 septum, 195, 199, 331 spinal cord, 673 spinal trigeminal nucleus, 669 striatum, 71,335,609,915 subiculum. 331 substantia nigra, 603,609, 955 suprachiasmatic nucleus, 225 supraoptic nucleus, 165 telencepbalon, 663 thalamus, 335, 755, 837 vagus nerve, 375,657, 743, 807 ventral tegmental area, 749 ventromedial nucleus, 521 zona compacta, 603 zona incerta, 521 zona reticulata, 603

Brain, human, 879 cyclo (His-Pro) neuropeptide neurotransmitter

Brain monoamines, 325 body temperature bombesin

y-MSH somatostatin-28 TRH

Brain mRNA, 651 adrenealectomy glucocorticoid opioid peptides solution hybridization

Brain receptors, 335 :~H-AVP neuropeptide

Brain tissue, 699 kidney, rat neuropeptides

Caerulein acetylcholine release, 49 amphibia, 457 CCK, 457 guanidine, 49 guinea pig, 49 myenteric plexus, 49 somatostatin, 49

Calcitonin, 63 central nervous system intestinal motility

Calcium, 273 chlorotetracycline /3-endorphin fluorescence

Cancer, 683 bombesin human studies neuroendocrine peptides

Capsaicin cysteamine, 669 guinea pigs, 769 mesenteric ganglia. 769 somatostatin, 669 substance P, 669, 769 sympathetic ganglia, 769

Cardiovascular regulation, 621 hindbrain nuclei opiate receptors

Cardiovascular responses alcohol, 563 autonomic nervous system. 617 catecholamines, 617, 971 chemoreceptors, 171 dependence. 563 depression, 563 dogs, 171,971 drinking, 563 eating, 563 endogenous opiates, 563 met-enkephalin. 971 epilepsy. 563 learning, 563 memory, 563 opioid peptides. 171 schizophrenia, 563 shock. 563 social behavior, 563 stress, 563,971 thyrotropin-releasing hormone (TRH).

617 tolerance, 563 vagal afferents, 171

Casomorphins. 283 deprolorphin field potentials hippocampus opioid peptides

/3-Casomorphins, 205 dogs enkephalins opiate receptors pancreatic polypeptides

Catecholamine-peptide interaction, 955 dopamine release in vivo studies neurotensin substantia nigra

Catecholamines autonomic nervous system, 617 bovine pancreatic polypeptide, 231 cardiovascular responses, 617, 97 I dogs, 971 dopamine-/3-hydroxylase, 23 I met-enkephalin, 971 stress, 97 I superior cervical ganglia, 231 thyrotropin-releasing hormone ITRH),

617 Cats

bombesin, 673 female genital tract, 387 neuropeptides, 387 rabbits, 387 somatostatin, 673 spinal cord, 673 substance P. 673

Caudal neurosecretory system, 367 neuropeptide sucker urophysis

Central amygdaloid nucleus, 525 neuropeptides peptidergic interactions

Central nervous system, 63 calcitonin intestinal motility

Central nervous system temperature control, 195

hyperthermia rabbits septum vasopressin

Central sympathetic outflow, 59 angiotensin ll endogenous opioid neurons /3-endorphin plasma catecholamines saralasin

Cerebral cortex, 133 apamin liver, hog neuropeptides uterine smooth muscle, hog vasoactive intestinal polypeptide

binding sites Cerebral osmostimulation, 843

dogs renal function t hyrolropin-releasing hormone

Chemoreceptors, 171 cardiovascu[ar responses dogs opioid peptides vagal afferents

[D-Trp ~] chicken LH-RH, 425 chickens chicken LH-RH agonist receptor binding activity LH-releasing activity

Chicken LH-RH agonist, 425 chickens I D-Trp ~1 chicken LH-RH

chemoreceptors, 171 cholecystokinin, 153 enkephalins, 205 met-enkephalin, 971 gastrin-releasing peptide, 153 interdigestive migrating contractions,

439 migrating myoelectric complex. 375 motilin, 375,439 opiate receptors, 205 opioid peptidcs, 171 pancreatic polypeptides, 153, 205 renal function, 843 stress, 971 thyrotropin-releasing hormone, 843 vagal afferents, 171 vagus nerve, 375

Dopamine-/3-hydroxylase, 231 bovine pancreatic polypeptide catecholamine superior cervical ganglia

Dopamine metabolism lesions. 6-hydroxydopamine, 6119 neurotensin. 6119 opioid regulation. 595 species differences, 595

Dopamine release. 955 cat hecholamine-peptide interaction in vivo studies neurotensin subslantia nigra

Dopaminergic neurons. 43 corpus striatum neurotensin nucleus accumbens aH-spiperone binding

Dose response, 31 antinociceplion n a l o x o n e substance P

Double labeling. 657 amygdala somatoslatin

Drinking alcohol, 563 angiotensin II, 103 anorcxia n e r v o s a , 85 anorexigenic peptide, 85 angiotensin II, 159 body weight. 85 cardiovascuhu" responses, 563 cholecystokinin octapeptide, 103 dependence. 563 depression, 563 eating, 85, 103, 563 endogenous opiates, 563 epilepsy, 563 growth, 85 hamsters. 103 hyperthermia, 85 learning, 563 memory. 563 metabolism. 85 neuropeptides. 493 paraventricular nucleus. 493 route of administration. 159 schizophrenia. 563 shock, 563 social behavior, 563 strain differences, 359 stress. 563 thermoregulalion. 85 tolerance. 563 wlgotomy, abdominal, 159 vasopressin, 359

Drug acetylcholine. 775,789 alcohol, 359 amphetamine, 749 d-amphetamine, 351,865 apomorphine, 43 ascorbate, 92 I atropine, 171, 325, 351, 375, 439 bretylium, 617 capsaicin, 669, 769 p-chloromercuribenzoate, 25 cimetidine, 35 I clonidine, 171. 351 copper, 25,921 cortisol, 775 cysteamine, 669 2-deoxy-D-glucose, 79 dexamethasone, 775. 785 diazepam, 35 I dihydroxyphenylacetic acid. 595 diphenhydramine, 351 dopamine, 351. 595,775, 837 d-Ala2-met-enkephalinamide. 239 epinephrine, 617,971 ethanol, 359 fenfluramine. 35 I fluphenazine, 693 glutamate, 837 guanidine, 49 haloperidol, 43, 351,393,693. 9117 hexamethonium, 171, 375 homowmillic acid, 595 6-hydroxydopamine, 6(}9 5-hydroxytryptamine, 955 impramine, 297 leukocytic pyrogen, 199 lithium, 4115 mercury, 25 methadone, 775 3-methoxytyramine, 595 ~-met hylparalyrosine, 325 methylphenidate, 775 methysergide, 325 morephine, 55, 2(}5,287, 351,417,603,

837, 907 naloxone, 31,49.55, 171,205. 287,325,

417, 631,647, 833, 859, 907 naltrexone, 117, 635 norepinephrine, 351,617, 775 ORG 2766, 1 I parazosin, 171 pentobarbital. 621 pentobarbitone. 617 1,10 phenanthroline. 25 phenoxybenzamine, 325, 351 phostigmine, 789 physostigmine, 775 picrotoxim 351 propranolol, 171, 325,351 reserpine, 231 serotonin, 775 sodium chloride, 843 sulpiride, 325 tolazoline. 351 yohimbine, 351

Drug discrimination. II ACTH analogues MSH/ACTH ~ ~,, ORG 2766

Dynorphin leu-enkephalin, 225 pituitary, 225 radioimmunoassay. 871 spontaneous hypertension. 225 strain differences, 225

Dynorphin~ ~:,, 125 f3-endorphin met-enkephalin gallbladder guinea pig terminal bile duct

Dynorphin (1-17). 797 mating opioids

Dynorphin selectivity, 915 /3-endorphin selectivity :~H-morphine binding multiple opiate receptors

Eating adrenal medulla. 807 alcohol, 563 angiotensin II, 103 anorexia nervosa, 85 anorexigenic peptide, 85 baboons. 687 body wcight. 85 bombesin, 1. 405, 687 cardiovascular responses, 563 cholecystokinin, 41/5 cholecystokinin, continuous infusion,

15 cholecystokinin octapeptide, 1, 103 corticotropin releasing factor (CRF),

8(}7 dependence, 563 depression, 563 drinking. 85, 103, 563 dynorphin (I-17), 797 endogenous opiates, 563 /3-endorphin, 79 epilepsy, 563 exploratory behavior, 41}5 fixed ratio shcedule, 351 growth, 85 hamsters, 11}3 hyperthermia, 85 hypothalamus, 287 learning, 563 lithium, 4(}5 meal pattern, 15 memory, 563 metabolism, 85 neuropeptides, 493 operant behavior, I opiates, 287 opioids, 797 opioid peptides, 79 oropharyngeal stimulus. I paraventricular nucleus, 287,493 plasma glucose, 687 plasma insulin, 687 satiety. I, 687 schizophrenia, 563 shock. 563 social behavior, 563 stress, 563 thermoregulation, 85 tolerance. 563 vagus nerve. 81}7

Electro-acupuncture, 5111 analgesia horses

Electroconvulsive shock, 293 amnesia passive avoidance somatostatin

Electrophysiology. 603 opiates substantia nigra

Endocrine cells, 245 enteric nerves enteroglucagon cells pancreas, rat pancreatic polypeptide

Endocrine system blood pressure, 211, 217 CRF, 211, 217 rhesus monkeys, 211, 217

Endogenous opiates, 563 alcohol cardiovascular responses dependence depression drinking eating epilepsy learning memory schizophrenia shock social behavior stress tolerance

Endogenous opioids, 631 animal models spinal cord injury

Endogenous opioid neurons, 59 angiotensin II central sympathetic outflow /3-endorphin plasma catecholamines saralasin

/3-Endorphin ACTH, 301,469, 789 age differences, 469 angiotensin II, 59 calcium, 273 central sympathetic outflow, 59 chlorotetracycline, 273 circadian rhythm, 305 conditioned avoidance, 19 cortisol, 19 41-CRF antiserum, 301 depression, 789 dynorphin~ ~a, 125 eating, 79 endogenous opioid neurons, 59 met-enkephalin, 125 fluorescence, 273 gallbladder, 125 guinea pig, 125 human studies, 469, 789 intermediate pituitary, 889, 897 /3-1ipotropin, 469 ~-MSH, 301 muscarinic receptors, 789 opiate activity, 889 opioid peptides, 79, 305 plasma catecholamines, 59 post-translational processing, 897 reptiles, 889, 897 rhesus monkeys, 19 saralasin, 59 shuttlebox, 19 stress, 19 terminal bile duct, 125

/3-Endorphin selectivity, 915 dynorphin selectivity :~H-morphine binding multiple opiate receptors

de.s-(1-13)/3-Endorphin, 191 circular dichroism phosphiesterase

des-Try-Endorphin, 393 haloperidol pineal melatonin levels

Enkephalin-containing polypeptide. 121 adrenal glands hypertension, spontaneous

Enkephalins. 205 /3-casomorphins dogs opiate receptors pancreatic polypeptide

Met-enkephalin cardiovascular response. 971 catecholamines. 971 dogs, 971 dynorphin~ ,:~, 125 /3-endorphin, 125 gallbladder. 125 guinea pig, 125 stress. 97 I terminal bile duct, 125

D-Ala'-'-metenkephalinamide, 239 hippocampus locomotor activity seizures, hippocampal shaking behavior theta rhythms thyrotropin-releasing hormone

Enteric nerves. 245 endocrine cells enteroglucagon cells pancreas, rat pancreatic polypeptide

Enteroglucagon cells, 245 endocrine cells enteric nerves pancreas, rat pancreatic polypeptide

Epilepsy ACTH, 315 alcohol. 563 cardiovascular responses, 563 dependence, 563 depression, 563 drinking, 563 eating. 563 endogenous opiates, 563 learning, 563 memory. 563 rabbits. 315 schizophrenia. 563 shock. 563 social behavior. 563 stress. 563 tolerance. 563

17/3-Estradiol, 97 amphibians arginine vasotocin 5~-dihydrotestosterone sexual behavior, male newts vasopressin antagonists

Exploratory behavior bombesin, 405 cholecystokinin (CCK), 405,743 eating. 405 lesions, nucleus tractus solitarius, 743 lithium. 405 satiety. 743

Female genital tract. 387 cats neuropeptides rabbits

Fever. 199 antipyresis ~-MSH rabbits septal region thermoregulation

Field potentials, 283 casomorphin deprolorphin hippocampus opioid peptides

Fixed ratio schedule eating. 351 Mk-771, 177 operant behavior. 177 pigeons. 177 rabbits. 177 species differences. 177 squirrel monkeys. 177 thyrotropin-releasing hormone. 177

Fluoresence. 273 calcium chlorotetracycline /3-endorphin

Food deprivation, 935 image analysis islet hormones islet morphology pancreatic islets

Forebrain. 837 corticotropin-releasing factor iontophoretic mapping

Gallbladder. 125 dynorphint ,:~ ¢3-endorphin met-enkephalin guinea pig terminal bile duct

Gastrin hexapeptide, 319 antral mucosa gastrin tetrapeptide isolation

Gastrin-releasing peptide. 153 cholecystokinin dogs pancreatic polypeptide

Gastrin tetrapeptide, 319 antral mucosa gastrin hexapeptide isolation

Gel filtration, 585 HPLC immunoreactive TRH

Gerbil. 801 arginine vasopressin seizures thermoregulation

Glucagon, 849 growth hormone secretion hypothalamic somatostatin

Glucocorticoid. 651 adrenalectomy brain mRNA opioid peptides solution hybridization

L-prolyl-L-arginyl-glycineamide, 401 chicks memory enhancement

Gonadotropin-releasing hormone. 821 proteolytic degradation rat ovary subeellular fractions

Grooming adrenalectomy, 907 bombesin, 907 hypophysectomy, 907 opiate receptors, 833

Growth, 85 anorexia nervosa anorexigenic peptide body weight drinking eating hyperthermia metabolism thermoregulation

Growth hormone, 929 craniopharyngioma human pancreatic GRF 1-40 prepubertal children prolactin

Growth hormone releasing factor immunocytochemistry, 521 in vitro studies, 107 pituitary. 107 pituitary growth hormone, 521

Growth hormone secretion, 849 glucagon hypothalamic somatostatin

Guanidine, 49 acetylcholine release caerulein guinea pig myenteric plexus somatostatin

Guinea pigs acetylcholine release, 49 bovine, 483 caerulein, 49 capsaicin, 769 dynorphin~ t:~, 125 /3-endorphin, 125 met-enkephalin, 125 gallbladder, 125 guanidine, 49 joining peptides, 483 kappa opiate receptors, 445 lung parenchyma, 581 mesenteric ganglia, 769 myenteric plexus, 49 opioid peptides, 445 peptide E, 445 porcine. 483 somatostatin, 49 substance P, 581,769 sympathetic ganglia, 769 terminal bile duct, 125 vasoactive intestinal peptide, 581

Haloperidol, 393 des-Try-endorphin pineal melatonin levels

Hamsters, 103 angiotensin II cholecystokinin octapeptide drinking eating

Heart rate autonomic responses, 37 blood pressure, 627 bradycardia, conditioned, 37 conditioning, Pavlovian, 37 learning, 37 neurohypophyseal peptides, 627 nictitating membrane, 37

rabbits, 37 vasopressin analogs, 37

Hindbrain nuclei, 621 cardiovascular regulation opiate receptors

Hippocampus casomorphin, 283 cholecystokinin, 331 deprolorphin, 283 D-Ala2-metenkephalinamide, 239 field potentials, 283 locomotor activity, 239 opioid peptides, 283 seizures, 239 shaking behavior, 239 subiculum, 331 theta rhythms, 239 thyrotropin-releasing hormone, 239

Histidyl-proline diketopiperazine, 89 adenylate cyclase adrenal cortex cyclo (His-Pro) specific binding monoamine oxidase thyrotropin releasing hormone

Hormone corticosterone, 725,729 cortisol, 19, 785 dihydrotestosterone, 97 estradiol, 97 growth hormone, 557, 849,929 insulin, 79 norepinephrine, 261 prolactin, 107,929

Horses, 501 analgesia electro-acupuncture

HPLC, 585 gel filtration immunoreactive TRH

Human pancreatic GRF 1-40, 929 craniopharyngioma growth hormone prepubertal children prolactin

Human studies ACTH, 469, 789 age differences, 469 bombesin, 683 cancer, 683 depression, 789 /3-endorphin, 469, 789 /3-1ipotropin, 469 major depressive illness, 297 memory, 707 MIF-I, 297 muscarinic receptors, 789 neuroendocrine peptides, 683 neuropeptides, 707 neurotensin, 543 vasopressin, 707

Hyperresponsive behavior, 421 startle response vasopressin

Hypertension, spontaneous, 121 adrenal glands enkephalin-containing polypeptide

Hyperthermia anorexia nervosa, 85 anorexigenic peptide, 85 body weight, 85 CNS temperature control, 195 drinking, 85 eating, 85 growth, 85

metabolism, 85 rabbits, 195 septum, 195 thermoregulation, 85 vasopressin, 195

Hypophysectomy, 907 adrenalectomy bombesin grooming

Hypothalamic-pituitary-adrenal axis, 775 affective disorders neurotransmitters

Hypothalamic-pit uitary-adrenal regulation, 785

ACTH cortisol depression

Hypothalamic-pituitary-thyroid axis, 735 lesions, hippocampal thyrotropin-releasing hormone

Hypothalamic somatostatin, 849 glucagon growth hormone secretion

Hypothalamo neurohypophyseal system, 165

age differences neurosecretory activity oxytocin thiamine pyrophospbatase vasopressin

Hypothalamus, 287 eating opiates paraventricular nucleus

Image analysis, 935 food deprivation islet hormones islet morphology pancreatic islets

Immunoreactive TRH, 585 gel filtration HPLC

Immunoreactivity, 111 chickens neurotensin radioimmunoassay

Immunocytochemistry biosynthesis, 963 growth hormone releasing factor, 521 lateral nucleus of the amygdala, 663 LHRH, 963 neuronal fibers, 557 pituitary growth hormone, 521 somatostatin, 557, 663

Interdigestive migrating contractions, 439 dogs motilin

Intermediate pituitary /3-endorphin, 889, 897 opiate activity, 889 post-translational processing, 897 reptiles, 889, 897

Intestinal motility analgesia, 577 calcitonin, 63 central nervous system, 63 dermorphin, 55, 577 morphine, 55 naloxone, 55 quaternary naloxone, 55

Intrathecal, 517 locomotor activity neurotensin

In vitro studies growth hormone-releasing factor, 107 oxytocin, 41 I pituitary. 107 pocin intestinal peptide. 817 prolactin secretion. 817 vasopressin, 411

In vivo studies, 955 catecholamine-peptkle interaction dopamine release neurotensin substantia nigra

lontophoretic mapping. 837 corticot ropin-releasing factor l\~rebrain

Inlet hormones, 935 food deprivation inlage analysis inlet morphology pancreatic inlets

Islet morphology, 935 lbod deprivation image analysis islet hormones pancreatic islets

Isolation. 319 antral mucosa gash'in hexapeptide gastrin tetrapeptide

Joining peptides bovine .ioining peptide. 475. 483 guinea pigs. 483 pituitary. 475 porcine. 483 pro-opiomelanocortin. 475

Kappa opiate receptors. 445 guinea pigs opioid peptides peptide E

Kidney, rat brain tissue, 699 neonatal exposure, vasopressin, 827 neuropeptides, 699 polyuria, 827 vasopressin, 827

Kyotorphiu+ 859 thermoregulation

Lateral nucleus of the amygdala, 663 immunocytochemistry somatostatin

l.earning alcohol. 563 autonomic responses, 37 bar press. 145 bradycardia, conditioned. 37 cardiovascular responses, 563 conditioning, Pavlovian, 37 dependence, 563 depression, 563 drinking. 563 eating. 563 endogenous opiates, 563 epilepsy. 563 heart rate, 37 melanotrc, pin receptors. 721 memory. 145+ 563. 71 I. 717. 721 +v-MSH. 145 [Nle'.D-PherI-¢~-MSH, 721 nictitating membrane, 37

open field, 717 photochamber activity, 717 rabbits, 37 schizophrenia, 563 shock. 563 social behavior, 563 strain differences. 711. 717 stress. 563 tolerance, 563 vasopressin, 71 I, 717 vasopressin analogs, 37 visual discrimination. 721 visual processes. 145 Y maze. 145

l.esions, hippocampal, 735 hy pothalamic-pit uitary-t h, reid axis thyrotropimreleasing hormone

Lesions. 6+hydroxydopamine. 61"19 dopamine metabolism n e u l ' o t e n s i n

Lesions, nucleus tractus solitarius, 743 cholecystokinin <CCK) explorator} behavior sutiet>

l.esions, paraventricular nucleus, 941 degeneration silver intensified PAP+method

LHRH biosynthesis. 963 chickens. 883 mmmnocytochemistry. 963 LH-releasing activity. 883 radioinlnlunoassay, 883

l.H-releasing activit} chickens. 425. 883 II)-Trp';I chicken I+H-RH. 425 chicken LH-RH agonist. 425 I.HRH. 883 radioimmunoassay. 883 receptor binding activity. 425

/3-l.ipotropin. 469 ACTH age differences /3-endorphin hum;m studies

Lithium. 405 bombesin cholccyslokinin eating exploratory I-,ehavior

Liver, hog. 13:~ apamin cerebru] cortex neuropeplides uterine smooth muscle, hog wtsoaclive intestinal polypeptidc

binding sites l+ocomotor activity

ACTH, ::.. 117 amphetamine. 749 biphasic effects. 117 bonlbesin. 693 cholec+~ slokinin, 749 defecation, 739 D+A Id-'-metenkephalinamide, 239 hippocampus, 239 intralhecal. 517 naltrexonc. 117 neuroleptics. 693 neuroreguhition. 739 netlrotensin. 5 17 novel object approaches. 739 open field. 749 secretin. 739 seizures, hippocampal. 239

shaking behavior, 239 theta rhythms, 239 thvrotropin-releasing hormone. 239

Leu-enkephalin, 225 dynorphin pituitary spontaneous hypertension strain differences

l.ung parenchyma, 581 guinea pigs subst;mcc P vasoactive intestinal peptide

l+uteinizing hormotm-rcleasing hormone. 25

neuropeptides netlrotensin peptidasc activity s} n a p t o s o m a l men1 b ra l l e

Luteinizing hormone-releasing hormone analogue+ 149

ovulation inhibition solid phase peptide synthesis

h,'hijor depressivc illness. 297 human studies MIF-I

Mammalian skin. 813 I l l a I l l In a ] S

mclanoc+vte-stim ulating hormone Mammals

mannnalian skin, 813 mehmocyt¢-stimulating hormonc. 813 netlrohypophysis. 509 pineal gland, 509 retina. 509 substance P..4+5 l sympathctic n¢lVOUS system. 451

Mammary adenocat+cinoma. 635 opioid pcptidcs stl 'eSs

Y maze. 145 bar press Icarning memory ++-MSH visual processcs

Meal Pattern. 15 cholecystokinin, continuous infusion eating

Melanocylc-stinmlating hormone eorlicosterone+ 725 discrmfination, 725 maznmaliat~ skin. 813 nmmmals. 813 ncuropcplidcs, 725 operant behavior. 725

Mclanotropin rcccptors, 721 Icat+nmg n l e n l o r y

[ N Ic '-l)-Phe:l-~- M S H visual discrimination

Memory alcohol, 5'~3

", q antivasopressin serum. _6. bar prcss, 145 cardiovascular responses, 563 dependence. 563 depression. 563 drinking. 563 eating, 563 endogenous opiates. 563 epilepsy. 563 human sludics, 7(17 learning. 145. 563. 71 I+ 717. 721 melanolropin receptors. 721

~-MSH, 145 [Nle~,PheZ]-c~-MSH, 721 neuropeptides, 707 open field, 711,717 passive avoidance, 265 photochamber activity, 71 l, 717 retention, 265 schizophrenia, 563 shock, 563 social behavior, 563 strain differences, 71 I. 717 stress, 563 tolerance. 563 vasopressin, 265,707, 711,717 visual discrimination, 721 visual processes. 145 Y maze, 145

Memory enhancement, 401 chicks L-prolyl- L-arginyl-glycineamide

Mesenteric ganglia, 769 capsaicin guinea pigs substance P sympathetic ganglia

Metabolism, 85 anorexia nervosa anorexigenic peptide body weight drinking eating growth hyperthermia thermoregulation

Method autoradiography, 755 binding assay, 699 chromatography, 543. 853 column chromatography, 245 electron microscopy, 941 gel filtration, 463, 585 high performance liquid

chromatography, 457. 483. 585 high pressure liquid chromatography,

463 immunocytochemistry, 521, 525,549,

557,663+ 963 immunoreactivity, 231,609 light microscopy, 549, 941 liquid chromatography. 311 radioimmunoassay. 111, 165. 301,311,

319, 343,451,457,475,483, 509, 543, 585, 853. 875, 935

radioligand binding assay, 255 recombinant DNA technology. 651 retrograde labeling, 657 silver intensified PAP-method. 941

MIF-I, 297 human studies major depressive illness

Migrating myoelectric complex. 375 dogs motilin vagus nerve

Mitotic index, 183 ACTH 1-17 circadian rhythm cornea placebo

MK-771, 177 fixed ratio schedule operant behavior pigeons rabbits species differences

squirrel monkeys t hyrotropin-releasing hormone

Molecular oxygen, 921 bovine intermediate pituitary peptide a-amidation

Monoamine oxidase, 89 adenylate cyclase adrenal cortex cyclo (His-Pro) specific binding histidyl-proline diketopiperazine thyrotropin releasing hormone

Morphine, 55 dermorphin intestinal motility naloxone quaternary naloxone

:~H-morphine binding, 915 dynorphin selectivity /3-endorphin selectivity multiple opiate receptors

Morphine withdrawal, 417 diapeptides naloxone

Motilin dogs, 375,439 interdigestive migrating contractions,

439 migrating myoelectirc complex. 375 vagus nerve, 375

Motor activity, 865 aging d-amphetamine circadian rhythms ~x-MSH thermoregulation

MSH/ACTH~ .,, 11 ACTH analogues drug discrimination ORG 2766

o~-MSH ACTH, 301 aging, 865 d-amphetamine, 865 antipyresis, 199 41-CRF antiserum, 301 bar press, 145 circadian rhythms, 865 /3-endorphin, 301 fever, 199 learning, 145 memory, 145 motor activity, 865 rabbits, 199 septal region. 199 thermoregulation, 199, 865 visual processes, 145 Y maze, 145

a-MSH metabolism, 5 absorption time route of administration

[Nle4,D-Pheq-a-MSH, 721 learning melanotropin receptors memory visual discrimination

y-MSH, 325 body temperature bombesin brain monoamines somatostatin-28 TRH

Multiple opiate receptors, 915 dynorphin selectivity /3-endorphin selectivity :~H-morphine binding

Muscarinic receptors, 789 ACTH depression /~-endorphin human studies

Myenteric plexus. 49 acetylcholine release caerulein guanidine guinea pig somatostatin

Naloxone antinociception, 31 dermorphin, 55 diapeptides, 417 dose response, 31 intestinal motility, 55 morphine, 55 morphine withdrawal. 417 quaternary naloxone. 55 substance P, 31

Naltrexone+ 117 ACTH, :~++ biphasic effects locomotor activity

Neonatal exposure, vasopressin, 827 kidney, rat polyuria vasopressin

Neuroendocrine peptides, 683 bombesin cancer human studies

Neurohypophyseal peptides, 627 blood pressure heart rate

Neurohypophysis, 509 mammals pineal gland retina

Neuroleptics, 693 bombesin locomotor activity

Neuromodulation, 261 cAMP norepinephrine vasopressin

Neuronal fibers, 557 immunocytochemistry somatostatin

Neuropeptides apamin, 133 :~H-AVP+ 335 brain, human, 879 brain receptors, 335 brain tissue, 699 cats, 387 caudal neurosecretory system, 367 central amygdaloid nucleus, 525 cerebral cortex, 133 corticosterone, 725 cyclo (His-Pro) discrimination. 725 drinking, 493 eating, 493 female genital tract, 387 human studies, 707 kidney, rat, 699 liver, hog, 133 luteinizing hormone-releasing

hormone, 25 melanocyte-stimulating hormone, 725 memory. 707

neurotensin, 25 neurotransmitter, 879 operant behavior, 725 paraventricular nucleus. 493 peptidase activity, 25 peptidergic interactions, 525 rabbits, 387 sucker. 367 synaptosomal membrane, 25 urophysis, 367 uterine smooth muscle, hog, 133 vasoactive intestinal polypeptide

binding sites, 133 vasopressin, 707 ventilation. 277

Neuropeptide Y, 381 pancreatic polypeptide vas deferens

Neuropeptide degradation, 71 cholecystokinin octapeptide solubilization synaptic membranes

Neuroregulation, 739 defecation locomotor activity novel object approaches sccretin

Neurosecretory activity, 165 age differences hypothalamo neurohypophyseal

system oxytocin thiamine pyrophosphatase vasopressin

Neurotensin catecholamine-peptide interaction, 955 chickens, II1 corpus striatum, 43 dopamine metabolism, 609 dopamine release, 955 dopaminergic neurons, 43 human studies, 543 immunoreactivity, 1 I 1 intrathecal, 517 in vivo studies, 955 lesions, 6-hydroxydopamine. 609 locomotor activity, 517 luteinizing hormone-releasing

hormone, 25 neuropeptides, 25 nucleus accumbens, 43 peptidase activity, 25 radioimmunoassay, I 11 :~H-spiperone binding, 43 substantia nigra, 955 synaptosomal membrane, 25

Neurotransmitter affective disorders, 775 brain, human, 879 cyclo (His-Pro). 879 hypothalamic-pituitary-adrenal axis.

775 neuropeptide, 879

Newts, 729 route of administration sexual behavior, male newts

Nictitating membrane, 37 autonomic responses bradycardia, conditioned conditioning, Pavlovian heart rate learning rabbits vasopressin analogs

Norepinephrine, 261 cAMP neuromodulation vasopressin

Novel-object approaches, 739 defecation locomotor activity neuroregulation secretin

Nucleus accumbens, 43 corpus striatum dopaminergic neurons neurotensin :~H-spiperone binding

Open field amphetamine, 749 cholecystokinin. 749 learning, 717 locomotor activity, 749 memory, 717 photochamber activity, 717 strain differences, 717 vasopressin, 717

Operant behavior bombesin, I cholecystokinin octapeptide, I corticosterone, 725 discrimination, 725 eating, 1 fixed ratio schedule, 177 melanocyte-stimulating hormone, 725 MK-771, 177 neuropeptides, 725 oropharyngeal stimulus, I pigeons. 177 rabbits, 177 satiety, 1 species differences, 177 squirrel monkeys, 177 thyrotropin-releasing hormone, 177

Opiates eating, 287 electrophysiology, 603 hypothalamus, 287 paraventricular nucleus, 287 substantia nigra, 603

Opiate activity, 889 ¢4-endorphin intermediate pituitary reptiles

Opmte receptors cardiovascular regulation, 621 /3-casomorphin, 205 dogs, 205 enkephalins, 205 grooming, 833 hindbrain nuclei, 621 opioid peptides, 647 ovariectomy, 647 pancreatic polypepfide, 205

Opioids, 797 dynorphin (I-17) eating

Opioid peptides adrenalectomy. 65 I brain mRNA, 651 cardiowiscular responses, 171 casomorphin, 283 chemoreceptors, 17 I circadian rhythm, 305 deprolorphin, 283 dogs. 171

eating, 79 fl-endorphin, 79, 305 field potentials, 283 glucocorticoid, 651 guinea pigs, 445 hippocampus, 283 kappa opiate receptors, 445 mammary adenocarcinoma, 635 opiate receptors, 647 ovariectomy, 647 peptide E, 445 solution hybridization, 651 stress, 635 vagal afferents, 171

Opioid regulation, 595 dopamine metabolism species differences

ORG 2766. I I ACTH analogues drug discrimination MSH/ACTH4 ~,,

Oropharyngeal stimulus. I bombesin cholecystokinin octapeptide eating operant behavior satiety

Ovariectomy, 647 opiate receptors opioid peptides

()vine CRF, 221 ACTH blood pressure cortisol sheep

Ovulation inhibition, 149 luteinizing hormone-releasing hormone

analogue solid phase peptide synthesis

Oxytocin age differences, 165 angiotensin iI, 137 hypothalamo neurohypophyseal

system, 165 in vitro studies, 411 neurosecretory activity, 165 steric parameter, 137 structure activity relationship, 137 thiamine pyrophosphatase, 165 vasopressin, 165, 411

Pancreas, rat, 245 endocrine cells enteric nerves enteroglucagon cells pancreatic polypeptide

Pancreatic islets, 935 food deprivation image analysis islet hormones islet morphology

Pancreatic polypeptide /3-casomorphins, 205 cholecystokinin, 153 dogs, 153, 205 endocrine cells, 245 enkephalins, 205 enteric nerves, 245 enteroglucagon cells, 245 gastrin-releasing peptide, 153 neuropeptide Y, 381 opiate receptors, 205 pancreas, rat, 245 vas deferens, 381

Paraventricular nucleus arginine-vasopressin, 875 biorhythm, 875 circadian rhythm. 875 drinking, 493 eating, 287, 493 hypothalamus, 287 neuropeptides, 493 opiates, 287 suprachiasmatic nucleus, 875 supraoptic nucleus, 875

Pars distalis, 431 N-terminal pro-opiocortin peptides pars intermedia

Pars intermedia, 431 N-terminal pro-opiocortin peptides pars distalis

Passive avoidance amnesia, 293 antivasopressin serum, 265 electroconvulsive shock, 293 memory, 265 retention, 265 somatostatin, 293 vasopressin, 265

[:~H]Pentagastrin, 755 binding assay cholecystokinin (CCK)

Peptidase activity, 25 luteinizing hormone-releasing hormone neuropeptides neurotensin synaptosomal membrane

Peptidase inhibitor, 639 aminoenkephalinase

Peptides ACTH, 211,221,301,469, 725,775,

785,789 ACTH 1-17. 183 ACTH (1-24), 833,907 ACTH~ :~, 117, 729 ACTH 4-10, 729 angiotensin II, 59, 103, 137, 159 anorexigenic peptide, 85 apamin, 133 arginine vasopressin, 195,509,627,

801,875 arginine vasotocin, 97, 627 avian pancreatic polypeptide, 387 bombesin, 1, 277, 325,405, 673,683,

687,693,907 bovine joining peptide, 475,483 bovine pancreatic polypeptide, 231 caerulein, 49, 457 calcitonin, 63, 277 casomorphin, 283 fi-casomorphin, 205 cholecystokinin, 15, 153,331,351,405,

457, 743,749, 755 cholecystokinin octapeptide, 1,71, 103 corticotropin, 431,921 corticotropin releasing factor, 211,217,

221,411, 807, 837, 941 cortisol, 221,501 cyclo (His-Pro), 89, 879 cyclo (N-methyI-L-Try-L-Arg), 859 deprolorphin, 283 dermorphin, 55,577 desmopressin acetate, 707 dynorphin, 225,445,631,915 dynorphin, ~:~, 125, 833 dynorphin (1-17), 797 dynorphin-32, 871 dynorphin B, 871 dynorphin B-29, 871

d es-tyrosine~-dynorphine(1-13), 833 /3-endorphin, 19, 59, 79, 125,273,301,

305,431,469, 501,789, 833,871, 889, 897, 915

des-(l-13) /3-endorphin, 191 des-try-endorphin, 393 enkephalins. 351, 387, 603,639 D-ala2-D-leuS-enkephalin, 205,621 D-AlaZ,MePhe4,Gly-oPenkephalin, 621 d-ala-2-met-5-enkephalin, 287 leu-enkephalin, 171, 205,225 met-enkephalin, 125,525. 859, 971 follicle stimulating hormone (FSH),

549, 647, 929 gastrin, 319 gastrin-releasing peptide, 153 glucagon, 849 2-L-leucyl- L-glycine, 417 L-prolyl- L-arginyl-glycineamide, 401 GnRH, 549 gonadotropin-releasing hormone, 821 growth hormone-releasing factor, 107,

521 histidyl-proline diketopiperazine, 89 immunoreactive TRH, 585 kyotorphin, 859 2-L-glutamyl-L-leucine, 417 2-L-prolyI-L-leucine, 417 2-prolyl-D-leucine, 417 lipotropin, 431 fl-lipotropin, 469 luteinizing hormone, 549,647, 843,929 luteninizing hormone-releasing

hormone. 25, 149, 425,883,963 melanocyte-stimulating hormone, 725 c~-melanocyte-stimulating hormone, 5,

145, 199. 301,721,729, 813,865, 921

3,-melanocyte-stimulating hormone, 325,921

y:~-melantropin, 431 MIF-I, 297 MK-771, 177 MRZ 2549, 621 motilin, 375,439 MSH/ACTHa . . 11 [NIe4,D-Pher]-a-MSH, 721 neuropeptide Y, 381 neurophysin, 509 neurotensin, 25, 43, 111,277, 493,517,

525,543,609, 907,955 (GIn4)-neurotensin, 543 oxytocin, 137, 165,411,509, 627,699 pancreatic polypeptide, 153, 205,245,

381 peptide E, 445 pituitary peptide, 359 porcine, 483 porcine intestinal peptide, 817 proenkephalin, 445 prolactin, 577 2- L-glycyI-L-proline, 417 pro-opiomelanocortin, 475 saralasin, 59 secretin, 739 somatostatin, 49, 277, 293, 367, 387,

525,557,669, 673,849,935 somatostatin-28, 325 substance P, 31,277,387, 451,517,

525, 581,669, 673,763, 769 thymosin a,, 463 thyrotropin-releasing hormone, 89,

107, 177, 239, 255,277, 311,325, 557, 617,631,735,817, 843,853, 859, 879

urotensin II, 367 vasoactive intestinal peptide, 525,581,

817 vasoactive intestinal polypeptide, 133,

387 vasopressin, 37, 165,261,265,359,

401, 411,421,699, 707, 711,717, 827

vasotocin, 401 Peptide c~-amidation, 921

bovine intermediate pituitary molecular oxygen

Peptide E, 445 guinea pigs kappa opiate receptors opioid peptides

Peptide localization, 463 biochemical characterization

Peptidergic interactions, 525 central amygdaloid nucleus neuropeptides

Phosphodiesterase, 191 circular dichroism des-(1-13)/3-endorphin

Photochamber activity, 717 learning memory open field strain differences vasopressin

Pigeons, 177 fixed ration schedule MK-771 operant behavior rabbits species differences squirrel monkeys t hyrotropin-releasing hormone

Pineal gland, 509 mammals neurohypophysis retina

Pineal melatonin levels, 393 des-Try-endorphin haloperidol

Pituitary bovine, 475 dynorphin, 225 growth hormone-releasing factor, 107 in vitro studies, 107 joining peptides, 475 leu-enkephalin, 225 pro-opiomelanocortin, 475 spontaneous hypertension, 225 strain differences, 225

Pituitary growth hormone, 521 growth hormone releasing factor immunocytochemistry

Placebo, 183 ACTH 1-17 circadian rhythm c o F n e a

mitotic index Plasma catecholamines, 59

angiotensin II central sympathetic outflow endogenous opioid neurons /3-endorphin saralasin

Plasma glucose, 687 baboons bombesin eating plasma insulin satiety

Plasma insulin, 687 baboons bombesin eating plasma glucose satiety

Polyuria. 827 kidney, rat neonatal exposure, vasopressin vasopressin

Porcine, 483 bovine .joining peptide guinea pigs .joining peptides

Porcine intestinal peptide, 817 in vitro studies prolactin secretion

Post-translational processing, 897 ,8-endorphin intermediate pituitary reptiles

Prepubertal children. 929 craniopharyngioma growth hormone human pancreatic GRF 1-40 prolactin

Prolactin, 929 craniopharyngioma growth hormone human pancreatic GRF 1-40 prepubertal children

Prolactin secretion. 817 in vitro studies porcine intestinal peptide

Pro-opiomelanocortin, 475 bovine joining peptides pituitary

Proteolytic degradation. 821 gonadotropin-releasing hormone rat ovary subcellular flactions

Quaternary mdoxone. 55 dermorphin intestinal motility morphine naloxone

Rabbits ACTH, 315 antipyresis. 199 autonomic responses, 37 bradycardia, conditioned, 37 cats. 387 CNS temperature control. 195 conditioning, Pavlovian. 37 epilepsy, 315 female genital tract, 387 fever, 199 fixed ratio schedule, 177 heart rate. 37 hyperthermia. 195 learning, 37 MK-771. 177 {~-MSH, 199 neuropeptides, 387 nictitating membrane, 37 operant behavior, 177 pigeons, 177 septal region. 199 septum, 195 species differences. 177 squirrel monkeys. 177 thermoregulation, 199

thyrotropin-releasing hormone, 177 vasopressin, 195 vasopressin analogs. 37

Radioimmunoassay chickens, I l l . 883 dynorphin. 871 immunoreactivity, I 11 LH-releasing activity, 883 LHRH, 883 neurotensin, I I I

Radioligand binding assay, 225 analeptics anesthesia barbiturates thyrotropin releasing hormone

Rat ovary. 821 gonadot ropin-releasing hormone proteolytic degradation rat ovary

Rat prostate. 853 amino acid analysis bioassay receptor assay t hyrotropin-releasing hormone

Receptor assay. 853 amino acid analysis bioassay rat prostate t hyrot ropin-releasing hormone

Receptor binding activity. 425 chickens I D-Trp 6] chicken LH-RH chicken LH-RH agonist gH-releasing activity

Renal function, 843 cerebral osmostimulation dogs t hyrot ropin-releasing hormone

Reptiles ~-endorphin, 889. 897 intermediate pituitary, 889, 897 opiate activity, 889 post-translational processing. 897

Retention. 265 anfivasopressin serum memory passive avoidance vasopressin

Retina, 509 mammals neurohypophysis pineal gland

Rhesus monkeys blood pressure, 211. 217 conditioned aw)idance, 19 cortisol, 19 CRF, 211. 217 endocrine system. 211, 217 /3-endorphin. 19 shutllebox. 19 stress. 19

Route of administration absorption time. 5 angiolensin 11, 159 drinking. 159 ~v-MSH metabolism. 5 newts. 729 sexual behavior, male newts. 729 vagotomy, abdominal, 159

Saralasin. 59 angiotensin 11 central sympathetic outflow endogenous opioid neurons

/3-endorphin plasma catecholamines

Satiety baboons, 687 bombesin, 1,586 cholecystokinin (CCK), 743 cholecystokinin octapeptide, 1 eating, 1,687 exploratory behavior. 743 lesions, nucleus tractus solitarius, 743 operant behavior, 1 oropharyngeal stimulus, I plasma glucose, 687 plasma insulin. 687

Schizophrenia, 563 alcohol cardiovascular responses dependence depression drinking eating endogenous opiates epilepsy learning memory shock social behavior stress tolerance

Secretin, 739 defecation locomotor activity novel object approaches

Seizures, 801 arginine vasopressin gerbil thermoregulation

Seizures, hippocampal, 239 D-Ala2-metenkephalinamide hippocampus locomotor activity shaking behavior theta rhythms t hyrot ropin-releasing hormone

Septal region. 199 antipyresis fever ~t-MSH rabbits t hermoregulation

Septum. 195 CNS temperature control hyperthermia rabbits vasopressin

Sexual behavior, male newts amphibians. 97 arginine vasotocin. 97 5~r-dihydrotestosterone. 97 17,~-estradiol. 97 newts, 729 route of administration, 729 vasopressin antagonists. 97

Shaking behavior. 239 D-Ala2-metenkephalinamide hippocampus locomotor activity seizures, hippocampal theta rhythms t hyrotropin-releasing hormone

Sheep, 22 I ACTH blood pressure cortisol ovine CRF

Shock. 563 alcohol cardiovascular responses dependence depression drinking eating endogenous opiates epilepsy learning memory schizophrenia social behavior stress tolerance

Shuttlebox. 19 conditioned avoidance cortisol /3-emlorphin rhcsus monkeys stress

Silver intensified PAP-method, 941 degeneration lesions, paraventricular nucleus

Social behavior, 563 alcohol cardiovascular responses dependence depression drinking eating endogenous opiates epilepsy learning memory schizophrenia shock stress tolerance

Solid phase peptide synthesis. 149 luleinizing hormone-releasing hormone

analogue ovulation inhibition

Solubilizalion. 7 I cholecystokinin oclapeptide neuropeptide degradation synaptic membranes

Sohltion hybridization, 65 I adrenalectomy brain mRNA glucocorticoid opioid peptides

Somatostatin acetylcholine release. 49 amnesia. 293 amygdala, 657 bombesin, 673 caerulein. 49 capsaicin. 669 cals. 673 cysteamine. 669 double labeling, 657 clectroconvuisive shock. 293 guanidine. 49 guinea pig. 49 immunocytochemislry. 557,663 lateral nucleus of the amygdala. 663 mycnteric plexus. 49 neuronal fibers. 557 passive avoidance, 293 spinal cord, 673 substance P. 669. 673

Somatostatin-28. 325 body temperature bombesin

brain monoamines T-MSH TRH

Species differences dopamine metabolism. 595 fixed ratio schedule. 177 MK-771, 177 operant behavior, 177 opioid regulation. 595 pigeons, 177 rabbits, 177 squirrel monkeys. 177 thyrotropin-releasing hormone. 177

Spinal cord, 673 bombesin cats somatostatin substance P

Spinal cord injury, 631 animals models endogenous opioids

:~H-Spiperone binding. 43 corpus striatum dopaminergic neurons neurotensin nucleus accumbens

Spontaneous hypertension, 225 dynorphin leu-enkephalin pituitary strain differences

Squirrel monkeys. 177 fixed ratio schedule MK-771 operant behavior pigeons rabbits species differences thyrotropin-releasing hormone

Startle response, 421 hyperresponsive behavior vasopressin

Steric parameter. 137 angiotensin II oxytocin structure activity relationship

Strain differences drinking, 359 dynorphin, 225 learning, 711, 717 leu-enkephalin, 225 memory, 711,717 open field, 71 I, 717 photochamber activity, 711, 717 pituitary. 225 spontaneous hypertension, 225 vasopressin, 359, 71 I, 717

Stress alcohol, 563 cardiovascular response, 563,971 catecholamines. 971 conditioned awfidance. 19 cortisol. 19 dependence. 563 depression. 563 dogs. 971 drinking. 563 eating. 563 endogenous opiates, 563 ,(3-endorphin. 19 epilepsy. 563 learning, 563 mammary adenocarcinoma. 635 memory. 563 opioid peptides. 635

rhesus monkeys. 19 schizophrenia. 563 shock. 563 shuttlebox. 19 social behavior. 563 stress. 971 tolerance. 563

Structure-activity relationships. 137 angiotensin Il oxytocin steric parameter

Subcellular fractions, 82 I gonadotropin-releasing hormone protcolytic degradation rat ovary

Subiculum. 331 cholecystokinin hippocampus

Substance P aggression. 763 antinociception. 31. 763 bombesin. 673 capsaicin. 669. 769 cats. 673 cysteamine. 669 dose response. 31 guinea pigs. 581. 769 lung parenchyma. 581 mammals. 45 I mesenteric ganglia. 769 naloxone. 3 I somalostatin. 669. 673 spinal cord. 673 sympathetic ganglia. 769 sympathetic nerwms system. 451 C-terminal. 763 N-terminal. 763 vasoactive intestinal peptide. 581

Substantia nigra catecholamine-peptide interaction. 955 dopamine release. 955 electrophysiology. 603 in vivo studies. 955 neurotensin. 955 opiates. 6()3

Sucker. 367 caudal neurosecretory system neuropeptide urophysis

Superior cervical ganglia. 231 bovine pancreatic poJypeptide catecholamine dopamine-,g-hydroxylase

Suprachiasmatic nucleus. 875 arginine-wlsopressin biorhythm circadian rhythm paraventricular nucleus supraoptic nucleus

Supraoptic nucleus, 875 arginine-vasopressin biorhythm circadian rhythm paraventricular nucleus suprachiasmatic nucleus

Sympathetic ganglia. 769 capsaicin guinea pigs rnesenteric ganglia substance P

Sympathetic nervous system. 451 mammals substance P

Synaptic membranes. 71 cholecystokinin octapeptide

neuropeptide degradation solubilization

Synaptosomal membrane. 25 luteinizing hormone-releasing hormone neuropeptides neurotensin peptidase activity

Synthetic peptides. 343 antibodies antigenic sites apolipoprotein A-II

Terminal bile duct. 125 dynorphin~ ~:~ /3-endorphin met-enkephalin gallbladder guinea pig

C-terminal fragments. 763 aggression antinociception N-terminal fragments substance P

N-terminal fragments. 763 aggression antinociception C-terminal fragments substance P

N-terminal pro-opiocortin peptides. 431 pars distalis pars intermedia

Thermoregulation aging. 865 d-amphetamine. 865 anorexia nervosa. 85 anorexigenic peptide. 85 antipyresis. 199 arginine vasopressin. 801 body weight. 85 circadian rhythms. 865 drinking. 85 eating. 85 fever. 199 gerbil. 801 growth. 85 hyperthermia. 85 kyotorphin. 859 metabolism. 85 motor activity. 865 a-MSH. 199. 865 rabbits. 199 seizures. 801 septal region. 199

Theta rhythms. 239 D-AIa'-'- mete nke phalinamide hippocampus locomotor activity seizures, hippocampal shaking behavior t hyrot ropin-releasing hormone

Thiamine pyrophosphatase. 165 age differences hypothalamo neurophypophyseal

system neurosecretory activity oxytocln vasopressin

Thyrotropin releasing hormone adenylate cyclase. 89 adrenal cortex. 89 alligators. 311 amino acid analysis. 853 analeptics. 255 anesthesia. 255 anorexia. 31 I autonomic nervous system. 617

barbiturates. 255 bioassay. 853 body temperature. 325 bombesin. 325 brain monoamines. 325 cardiovascular responses. 617 cerebral osmostimulation. 843 cyclo (His-Pro) specific binding. 89 dogs. 843 D-Ala~-metenkephalinamide. 239 fixed ratio schedule. 177 hippocampus. 239 histidyl-proline diketopiperazine. 89 hypothalamic-pituitary-thyroid axis.

735 lesions, hippocampal. 735 locomotor activity. 239 MK-711. 177 monoamine oxidase. 89 3,-MSH. 325 operant behavior. 177 pigeons. 177 rabbits. 177 radioligand binding assay. 255 rat prostate. 853 receptor assay. 853 renal function. 843 seizures, hippocampal. 239 shaking behavior. 239 somatostatin-28. 325 species differences. 177 squirrel monkeys. 177 theta rhythms. 239

Tolerance alcohol. 563 avoidance. 67 cardiovascular responses. 563 cholecystokinin octapeptide. 67 dependence. 563 depression. 563 drinking. 563 eating. 563 endogenous opiates. 563 epilepsy. 563 learning. 563 memory. 563 schizophrenia. 563 shock. 563 social behavior. 563 stress. 563

Urophysis. 367 caudal neurosecretory system neuropeptide sucker

Uterine smooth muscle, hog. 133 apamin cerebral cortex liver, hog neuropeptides vasoactive intestinal polypeptide

binding sites

Vagal afferents. 171 cardiovascular responses chemoreceptors dogs opioid peptides

Vagotomy. abdominal. 159 angiotensin 11 drinking route of administration

Vagus nerve adrenal medulla. 807 corticotropin releasing factor (CRF).

807

dogs. 375 eating. 807 migrating myoelectric complex. 375 motilin. 375

Vas deferens. 381 neuropeptide Y pancreatic polypeptide

Vasoactive intestinal peptide. 581 guinea pigs lung parenchyma substance P

Vasoactive intestinal polypeptide binding sites. 133

apamin cerebral cortex liver, hog neuropeptides uterine smooth muscle, hog

Vasopressin age differences. 165 cAMP. 261 antivasopressin serum. 265 CNS temperature control. 195 drinking. 359 human studies. 707 hyperresponsive behavior. 421 hyperthermia. 195 hypothalamo neurohypophyseal

system. 165 in vitro studies. 411 kidney, rat. 827 learning. 711. 717 memory. 265. 707. 711. 717 neonatal exposure, vasopressin. 827 neuropeptides. 707 neuromodulation. 261 neurosecretory activity. 165 norepinephrine. 26 I open field. 711. 717 oxytocin. 165. 411 passive avoidance. 265 photochamber activity. 711. 717 polyuria. 827 rabbits. 195 retention. 265 septum. 195 startle response. 421 strain differences. 359 .7 l l . 717 thiamine pyrophosphatase. 165

Vasopressin analogs. 37 autonomic responses bradycardia, conditioned conditioning. Pavlovian heart rate learning nictitating membrane rabbits

Vasopressin antagonists. 97 amphibians arginine vasotocin 5~-dihydrotestosterone 17/3-estradiol sexual behavior, male newts

Ventilation. 277 neuropeptides

Visual discrimination. 721 learning melanotropin receptors memory [NIeLD-Phe;]-c~-MSH

Visual processes. 145 bar press learning memory ~-MSH Y maze

A U T H O R I N D E X

Akutsu, Y., 859 Allevard, A. M., 509 Aloyo, V. J., 833 Alpert, J. E., 749 Amit, Z., 117 Anthony, E. L. P., 963 Antoni, F. A., 411 Antoni, G., 469 Aponte, G., 935 Appel, N. M., 59 Applebaum, L., 305 Arai, H., 439 Arcari, G., 577 Arimura, A., 107 Asaoka, H., 125

Bal~tspiri, L., 417 Banay-Schwartz, M., 639 Barchas, J. D., 853 Barrett, J. E., 177 Baskin, D. G., 699 Battaini, F., 89 Bayorh, M., 827 Beckwith, B. E., 707, 725 Bedford, J. A., 351 Beinfeld, M. C., 331 Bellush, L., 11 Benjanet, S., 509 Berger, H., 821 Bernardini, G. L., 195, 199 Bertness, V., 683 Bhatnagar, P. K., 343 Biggins, J. A., 585 Birnberg, N., 651 Blair, R., 117 Bo, P., 315 Bolaffi, J. L., 311 Boll6k, 1., 293 Bossut, D. F. B., 501 Boudouresque, F., 301 Brantl, V., 205 Briatico, G., 577 Brenneman, D. E., 331 Briggs, J., 915 Brown, T. S., 735 Bucsics, A., 451 Bueno, L., 63 Bui, N. D., 71 Burke, R. E., 43

Campbell, G. T., 843 Carasso, R. L., 865 Carey, R. J.. 711,717 Carlson, H. E., 915 Carney, D. N., 683 Carraway, R. E., I 11 Castanas, E., 301 Celia, S. G., 929 Cesana, R., 55 Chakrabarti, A. K., 273 Chalmers. R., 813 Chang, T.-M., 375 Charlton, C. G., 739 Chase, T. N., 67

Chatterjee, T. K., 273 Chepkova, A. N., 283 Cherkin, A., 401 Chey, W. Y., 375 Childs (Moriarty), G. V., 549,

557 Civelli, O., 651 Chmielowiec, S., 557 Chretien, M., 509 Chrousos, G. P., 521 Church, A. C., 261 Clark, W. G., 195 Codaccioni, J. L., 301 Cohen, S. L., 67 Colurso, G. J., 305 Comb, M., 651 Concannon, J. T., 1 I Conte-Devolx, B., 301 Cook, W., 145 Corda, R., 929 Cornett, L. E., 699 Cornwell, N. N., 359 Costantini, M. G., 335 Couk, D. I., 707 Court, J. A., 585 Cowan, A., 907 Cox, B. M., 225 Crawford, I. L.. 239 Crawley, J. N., 405, 739, 743 Crema, G., 55 Critcher, E. C., 359 Cuisinaud, G., 509 Culler, M. D., 107

Dallman, M., 785 Davis. J. L., 401 Davis, J. M., 79 Day, W. A., 883 DE Castiglione, R., 577 DEGuzman, T., 639 DEKrey, E. A., 725 DE LA Fuente, A., 205 Denson, D., 351 Deschodt-Lanckman, M., 71 Deupree, D., 1 DEWald, D., 121 DIAugustine, R. P., 475,483 Dimaline, R., 457 DI Salle, E., 577 Dockray, G. J., 319 Dodd, P. R., 25 Dorsa, D. M., 699 Doi, Y., 875 Dores, R. M., 889, 897 Douglass, J., 651 Drust, E. G., 239 Dudley, C. A., 837

Eberly, L. B., 837 Edwardson, J. A., 25, 585 Eipper, B. A., 921 I~rchegyi, J., 149 Erisman, M. D., 475,483

Facchinetti, F.. 469 Faden, A. I., 225,617,621,627,

631 Fagre, L. O., 769 Fahn, S., 43 Fahrenkrug, J., 133, 387 Fanni, V., 929 Ferre, J. P., 63 Feuerstein, G., 225,617,621,

627 Figlewicz, D. P., 687 Fioramonti, J., 63 Fisher. C., 813 Flerko, B., 149, 941 Fliers, E., 165 Forrester, D., 145

Gaffori, O., 393 Gainer, H., 827 Gale, R. P., 635 Galina, Z. H., 117 Gammeltoft, S., 133 Gandreau, P., 755 Gash, D. M., 421 Gauquelin, G., 509 Geelen, G., 509 Geffard, M., 393 Genazzani. A. R., 469 Gharib, C., 509 Ghosh, J. J., 273 Gibson, M. J., 305 Giedroc, D. P., 191 Giles, T. D., 171,971 Gillin, J. C., 789 Gilmore, J. P., 843 Giraud, P., 301 Gispen, W. H., 833 Glembotski, C. C., 921 Glyn-Ballinger, J.. 199 Gmerek, D. E., 907 Goldstein, A. L., 463 Gonder, J. C., 221 Gori, E., 55 Gosnell, B. A., 807 Gotto, A. M., Jr., 343 Gram, B. R., 387 Gray, T. S., 663 Green, B., 631 Gregory, R. A., 319 Groot, K., 107 Gross, D., 935

Hadley, M. E., 721 Halberg, F., 183 Hall, M. E., 31,763 Hancock, M. B., 549 Handelmann, G. E., 145,331,

721,739, 827 Hardy, J. A., 25 Hashimoto, H., 875 Hassen, A. H., 617, 621 Hazum, E., 549 Helke, C. J., 669, 673 Hepler, J. R., 85

Herbert, E., 651 Hern~indez, L. L., 37 Hershman, J. M., 915 Hewlett, W. A., 853 Higgins, G. A., 657 Hirsch, M. D., 255 Hoebel, B. G., 287,493 Hoffman, G. E.. 525 Holahan, W., 85 Holland, A., 205 H611t, V., 871 Holmes, M. C., 411 Holzer, P., 451 Hommer, D. W., 603 Hope, J., 431 Hruby, V. J., 721 Hsiao, S., 1, 15 Huey, L. Y., 775 Huffman, L. J., 843 Hui, K.-S., 639 Hui, M., 639 Hunsinger, R. N., 351 Hylden. J. L. K., 517

Imura, H., 849 lnoue, K., 153 Isenhour, J. L., 265 Itoh. Z., 439 lversen, S. D., 749

Jackson, I. M. D., 311 Jackson, S., 431 Jacobowitz, D. M., 231,381,

521 Jacobs, T. P., 631 Jahnke, G. D., 475,483 Janowsky, D. S., 775,789 Jew, J. Y., 769 Jiang, D., 43 Johnson, D. E., 581 Johnston, S., 693 Jones, M. T., 411 Joseph, M., 785 Judd, L. L., 775

Kalin, N. H., 19, 211,217. 221 Kastin, A. J., 563 Katakami, H., 849 Kato, N., 875 Kato, Y., 849 King, J. A., 425. 883 King, J. C., 963 Kirtland, S., 627 Kisara, K., 859 Knight, M., 67 Kobobun, K., 721 Koch, Y., 89 Koulischer, D., 71 Kova_cs, G. L., 417 Kov~ics, M., 149 Kraemer, G. W., 211,217 Krieger, D. T.. 305

Lajtha, A., 639 Lamb, D. R., 79

Lance. V.. 311 Lazarus , L. H.. 475,483 Leccese , A. P., 265 Lederis , K.. 367 Lee, K. Y., 375 Lee, R. J., 801 Lee, T. F., 955 Legros, ,I. J., 509 Leibowitz. S. F., 493 Lembeck , F., 451 Lengwiri. I., 941 Leshin , L. S., 501 Levine, A. S., 277, 797. 807 Lewis, J. W., 635 Lewis, R. V., 121 Liebeskind, J. C., 635 Ling, N. . 191,639 Lingle, P. F., 49 Liposits , Zs. , 941 Lipton, J. M., 195, 199 Lissi tzky, J. C., 651 Locatelli, V.. 929 Loche, S., 929 Loeser , B., 335 Loh, H., 871 Lomax , P., 801 Long, D. W.. 735 Loriaux, D. L., 521, 647 Louis . F., 509 Lowry, P. J., 431 Lowy, M. T., 79 Luciano, M. G., 107 Lumpkin , M. D., 817

McCann, S. M., 817 McDermot t . J. R., 25. 585 McDonald , J. K. , 817 McKay , D., 153 McKinney , W. T.. 211, 217 McLean , S., 287 McMaster , D., 367 Maier, V., 205 Mains, R. E., 921 Majumdar , L. A., 699 Maloney, R. E., Jr., 11 Malsbury, C. W., 103 Malven, P. V.+ 79, 501 Mat). S. J. T., 343 Martignoni, E., 469 Massari , V. J., 673 Matsumura , H., 859 Matsushi ta , N., 849 Matthies, H., 283 Maurelli, M., 315 Medzihradszky, K., 137 Mehlis, B., 821 Mendel, V., 935 Merali. Z., 693 Merriam, G. R., 647 Mcunier, C., 509 Mez6, I.. 149 Miceli, M. O., 103 Millar, R. P., 425, 883 Miller, C., 319 Miller, L. J., 97, 593, 729 Miller, M.. 711, 717 Miller, R. L., 739 Millet, Y., 301

Minuto, F., 929 Mitsutake, T., 125 Miyagawa, M., 125 Molineaux, C. J., 225 Moody, T. W., 463, 673,683 Moore, F. 1+., 97, 729 Mori. M., 879 Morley, ,I. E., 277, 797, 807 Moss. R. L., 837 M/hller, E. E., 929 Murphy, H. M., 735 Myers. R. D.. 85, 359, 955

Nfidasdi, L., 137 Nakajima+ T., 875 Nakaya , M.. 439 Naor, Z., 549 Nappi, G., 469 Nelson. J. B., 331 Nelson, L. R., 635 Niewoehner , D. E., 277 Nikolics, K.. 821 Noto+ T., 875

Obara, N.. 107 O 'Donohue , T. L., 145, 331,

463, 673, 721, 739 Ohhashi , T., 381 ()liver, C.. 301 Olschowka, J. A.. 231 OIson, G. A., 563 Olson, R. D., 563 Oouchi , M., 125 Ottesen, B.. 133. 387

Palaszynski , E. W., 463 Park, C. H., 673 Park, H. J., 375 Parker, C. R., Jr. , 879 Parohtro. D., 55 Paroutaud, P,, 71 Pan-ini. D., 469 Pauly. J. E., 183 Pearlmutter , A. F., 335 Pegues, J., 879 Pekary, A. E., 915 Penny, R. J., 813 Perseo, G., 577 Perl, A.. 61)3 Pert, C. g . , 755 Peterkofsky, A.. 89 Petracca, F. M., 699 Petraglia, F., 469 Pfeiffer, A.. 647 Pfeiffer, D. G., 647 Pfeiffcr, E. F., 205 Pico, R. M., 401 Pintor. C., 929 Porte. D., Jr,, 687 Powell, D. A., 37 Prasad, C., 879 Puett. D., 191

Ouirion, R., 445, 609, 755

Rausch, J. L., 775 Rayford, P. L., 153 Reches , A., 43 Reeve, J. R., Jr., 319

Regal, J. F.. 581 Reus, V. 1., 785 Rey, M., 301 Reymann , K. G., 283 Rice, .1. C., 971 Ridley, K., 813 Risch, S. C., 19, 775, 789 Ritsema, R. S., I l l Rivier, J. E., 107, 883 Roeske, R. W., 883 Rosenberger , J. G.. 225 Rosenquist , G.. 935 Rossi, A. . 577 Ruane, S. E., III Rush, D. R.. 19 Rushing, A., 725 Russell , J. T.. 827

Sakurada, S., 859 Sakurada, T., 859 Sala, M., 55 Salacinski, P., 431 Samson, W. K., 817 Sander. G. E., 171, 971 Sandman, C. A., 593 Sasaki, Y., 859 Savoldi, F.. 315 Sawyer, T. K., 721 Scallet, A. ( ' . . 19 Schally, A. V,, 941 Schechter , M. D., I I Scheving. L. E., 183 Schick. R., 205 Schneider, 1+. H., 749 Schulle, H., 521 Schusdziarra , V., 205 Schwaber , J. S., 657, 743 Seidah, N. G.. 509 Selsky, J. H., 669 Seprodi, J., 149 Sharp. B., 915 Shavit, Y., 635 Shelton, S. E., 21 I. 217, 221 Shibasaki, T., 325 Shimatsu, A., 849 Shimohigashi , Y., 647 Shively, J. E., 319 Shuster , S., 813 Simansky, K. J., 159 Sj(Squist, A., 133 Smith, A. I., 25, 585 Smith, G. P.. 159, 631 Soldato, C. M,, 475, 483 Sparrow, J. T., 343 Spazzi, L.. 55 Specht+ J., 205 Spruijt, B., 833 Stanley, B. G., 493 Staun-()lsen, P., 33 St-Pierre, S., 755 Stein, L. J., 687 Stewart , J. M., 31 763 S/romberg, M. W., 501 Strosberg. A. D., 71 Suomi, S. J., 19 Surprenant , A,, 889 Sutherland, C,, 117 Suzuki, K., 859

Suzuki, T., 439 Swabb, D. F., 165 Sz6ke, B.. 821 Szonttigh, L., 417

Takahara, Y., 89 Tamminga , ('. A., 67 Tartara, A.. 315 Taylor, I. L.. 245 Telegdy, G., 293,417 Tepl~in, 1., 149 Terman, G. W., 635 Theodorsson-Norhe im, E.. 543 Thody, A. J., 813 Thomas , C. R., 107 Tibolt. R., 549 Till, T. S., 71)7 Tizabi. Y., 673 Tobler, C. J., 883 TollelMm, S., 191 Tonegawa, Y., 325 Tsai, T. H., 183 Turkelson, C. M., 107

Uhler, M., 651

Vaillant, C. R.. 245 Vale. W., 107 VAN DER Velde, ('. D., 297 Van Loon. G. R., 59 VAN Ree. J+ M., 393 Vdcsei, L., 293 Vigh. S.. 941 Villa, F,, 929

Wagner. H. R.. 43 Wakabayashi , 1., 325 Wakabayashi , K., 439 Wang, C. H., 15 Warren, P. H.. 421 Watanabe, S., 859 Weiss, A. S., 445 West lund, K. N., 549. 557 Wideman, C. H., 735 Wilber, J. F., 879 Wilcox, G. I,.. 517 Wilkin, L. D., 769 Williams, A. R., 711, 717 Williams, T. H., 769 Wilson, J. F., 5 Wilson. M. C., 351 Wood, P. L., 595 Woods. S. C., 687 Wray, S., 525 Wright, A., 5

Yafima, H., 153 Yamada, T., 935 Yau. W. M., 49 Yehuda, S., 865 Yim, G. K. W., 79 Youlher, M. 1,., 49

Zaas, T.. 19 Zalcman, S., 693 Zerbe, R. L., 627, 827 Zhu, Y. X., 871 Zivin. J. A., 631 Zwiers. H.. 833